CA2144475C - Polyamide-oligonucleotide derivatives, their preparation and use - Google Patents

Polyamide-oligonucleotide derivatives, their preparation and use Download PDF

Info

Publication number
CA2144475C
CA2144475C CA2144475A CA2144475A CA2144475C CA 2144475 C CA2144475 C CA 2144475C CA 2144475 A CA2144475 A CA 2144475A CA 2144475 A CA2144475 A CA 2144475A CA 2144475 C CA2144475 C CA 2144475C
Authority
CA
Canada
Prior art keywords
dna
formula
pna
zero
polyamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2144475A
Other languages
French (fr)
Other versions
CA2144475A1 (en
Inventor
Eugen Uhlmann
Gerhard Breipohl
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hoechst AG
Original Assignee
Hoechst AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoechst AG filed Critical Hoechst AG
Publication of CA2144475A1 publication Critical patent/CA2144475A1/en
Application granted granted Critical
Publication of CA2144475C publication Critical patent/CA2144475C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/595—Polyamides, e.g. nylon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003—Peptide-nucleic acids (PNAs)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Polyamides (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Polyamide-oligonucleotide derivatives, their preparation and use Polyamide-oligonucleotide derivatives of the formula F[(DNA-Li)q(PNA-Li)r(DNA-Li)s(PNA)t]x F' wherein q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t >= 2; x is 1 to 20; DNA is a nucleic acid such as DNA or RNA or a known derivative thereof; Li is a covalent linkage between DNA and PNA, where the covalent linkage comprises a bond or an organic radical with at least one atom from the series consisting of C, N, O or S; PNA is a polyamide structure which contains at least one nucleotide base which is different from thymine; and F and F' are end groups and/or are linked together by a covalent bond, and the physiologically tolerated salts thereof, a process for their preparation and their use as pharmaceutical, as gene probe and as primer, are described.

Description

Hoechst Aktiengesellschaft HOE 94/F 057 Dr. WI/pp Description Polyamide-oligonucleotide derivatives, their preparation and use The present invention relates to novel polyamide-oligonu-cleotide derivatives with valuable physical, biological and pharmacological properties. Their application relates to use as inhibitors of gene expression (antisense oligonucleotides, ribozymes, sense oligonucleotides and triplex forming oligonucleotides), as probes for detec-ting nucleic acids and as aids in molecular biology.
Oligonucleotides are finding increasing application as inhibitors of gene expression (G. Zon, Pharmaceutical Research 5, 539 (1988); J.S. Cohen, Topics in Molecular and Structural Biology 12 (1989) Macmillan Press;
C. Helene and J.J. Toulme, Biochimica et Biophysica Acta 1049, 99 (1990); E. Uhlmann and A. Peyman, Chemical Reviews 90, 543 (1990)). Antisense oligonucleotides are nucleic acid fragments whose base sequence is complemen-tary to that of an mRNA to be inhibited. This target mRNA
can be of cellular, viral or other pathogenic origin.
Suitable cellular target sequences are, for example, those of receptors, cell-adhesion proteins, enzymes, immunomodulators, cytokines, growth factors, ion channels or oncogenes. Inhibition of virus replication with the aid of antisense oligonucleotides has been described, for example, for HBV (hepatitis B virus), HSV-1 and -2 (herpes simplex virus type I and II), HIV (human immuno-deficiency virus) and influenza viruses. This entails use of oligonucleotides which are complementary to the viral nucleic acid. Sense oligonucleotides are, by contrast, designed to have a sequence such that, for example, they bind ("trap") nucleic acid-binding proteins or nucleic acid-processing enzymes and thus inhibit their biological activity (C. Helene and J.J. Toulme, Biochimica et Biophysica Acta 1049, 99 (1990)). Viral targets which may be mentioned here are, for example, reverse transcriptase, DNA polymerase and transactivator proteins. Triplex-forming oligonucleotides generally have the DNA as target and, after binding thereto, form a triple helix structure. Whereas in general the processing (splicing etc.) of the mRNA or translation thereof into protein is inhibited by antisense oligonucleotides, the transcription or replication of the DNA is inhibited by triplex-forming oligonucleotides (C. Helene and J.J. Toulme, Biochim. Biophys. Acta 1049 (1990) 99-125;
E. Uhlmann and A. Peyman, Chemical Reviews 90, 543 (1990)). However, it is also possible to bind single-stranded nucleic acids in a first hybridization with an antisense oligonucleotide to form a double strand, which then in a second hybridization with a triplex-forming oligonucleotide forms a triplex structure. The antisense and triplex binding regions may in this case be accommo-dated either in two separate oligonucleotides or else in one oligonucleotide. Another application of synthetic oligonucleotides comprises so-called ribozymes which destroy the target RNA as a consequence of their ribonuclease activity (J.J. Rossi and N. Sarver, TIBTECH
(1990) 8, 179; Castanetto et al., Critical Rev. Eukar.
Gene Expr. (1992) 2, 331).

The compounds according to the invention can also be used in therapy in the sense of aptamers. Aptamers are oligo-meric nucleic acids or analogs thereof which bind with high affinity to proteins. The aptamers are found by in vitro selection from a random mixture (Famulok and Szostak (1992) Angew. Chem. 104, 1001-1011) and this has been carried out successfully for a thrombin-binding aptamer (Bock et al. (1992) Nature 355, 564-566). The procedure for this can be such that the base sequence of the aptamer is determined by screening an oligonucleotide mixture, and this base sequence is then transferred to polyamide-oligonucleotide analogs. Another possibility comprises encoding the binding region of the aptamer, to facilitate identification, by a separate non-binding part of the molecule (Brenner and Lerner (1992) PNAS 89, 5381-5383).

In DNA diagnosis, nucleic acid fragments with suitable labeling are used as so-called DNA probes for specific hybridization onto a nucleic acid to be detected. The specific formation of the new double strand is in this case followed with the aid of the labeling, which is preferably non-radioactive. It is possible in this way to detect genetic, malignant or viral diseases or diseases caused by other pathogens.

Oligonucleotides in their naturally occurring form have little or no suitability for most of the said applica-tions. They have to be chemically modified so that they satisfy the specific requirements. For oligonucleotides to be employable in biological systems, for example for inhibition of virus replication, they must meet the following requirements:
1. They must have sufficiently high stability under in vivo conditions, that is to say both in serum and intracellularly.
2. Their properties must be such that they can pass through the cell membrane and nuclear membrane.
3. Under physiological conditions they must bind in a base-specific manner to their target nucleic acid in order to display the inhibitory effect.

Points 1 to 3 are not a requirement for DNA probes;
however, these oligonucleotides must be derivatized so that detection is possible, for example by fluorescence, chemiluminescence, colorimetry or specific staining (Beck and Koster, Anal. Chem. 62, 2258 (1990)). The chemical modification of the oligonucleotides usually takes place by appropriate modification of the phosphate backbone, ribose unit or the nucleotide bases (J.S. Cohen, Topics in Molecular and Structural Biology 12 (1989) Macmillan Press; E. Uhlmann and A. Peyman, Chemical Reviews 90, 543 (1990)). Another frequently used method is to prepare oligonucleotide 5' conjugates by reaction of the 5'-hydroxyl group with appropriate phosphorylation reagents. If, on the other hand, all the internucleotide phosphate residues are modified there is often a drastic change in the properties of the oligonucleotides. For example, the solubility of methyl phosphonates in aqueous medium is greatly reduced, while all-phosphorothioate oligonucleotides often act in a non-sequence-specific manner.

There have recently been descriptions of polyamide-nucleic acid derivatives (Michael Egholm, Peter E. Nielsen, Rolf H. Berg and Ole Buchardt, Science 1991, 254, 1497-1500; WO 92/20702; M. Egholm et al. Nature (1993) 365, 566-568; P. Nielsen, (1994) Bioconjugate Chem. 5, 3-7) which bind to complementary target sequences (DNA or RNA) with higher affinity than natural oligonucleotides. These so-called peptide or polyamide nucleic acids (PNA) are DNA-analogous compounds in which the deoxyribose phosphate skeleton has been replaced by a polyamide oligomer. These compounds have the advantage compared with natural oligonucleotides that they are very stable in serum. However, on the other hand, they have the following disadvantageous properties:
(1) The amount taken up in cells is zero or undetectable.
However, since antisense or triplex-forming oligonucleo-tides are able to display their activity only in the cell, the PNAs as such are unsuitable for inhibition of gene expression in vivo.
(2) The PNAs tend to aggregate in aqueous solution, that is to say also under physiological conditions. Their solubility in aqueous buffer is therefore low and they are unavailable for hybridization to complementary sequences.
(3) The PNAs additionally have high affinity for various materials such as Sephadex (from Pharmacia) or Bond Elut (from Varian) used to purify the oligomers, so that the PNAs can often be isolated only in poor yields.

(4) Another serious disadvantage of the PNAs is that they do not bind in an unambiguous orientation to complementary nucleic acids. The sequence specificity is therefore reduced by comparison with natural oligonucleo-tides. Whereas natural nucleic acids generally hybridize to complementary nucleic acids in the antiparallel orientation, PNAs may bind both in the antiparallel and in the parallel orientation.
(5) WO 92/20702 mentions an oligonucleotide-PNA conjugate (T) 7 (5'-L-N)(t)6-Ala (Fig. 25; substitute sheet), where (T)7 is a natural heptathymidylate oligonucleotide which is linked via its 5'-O-phosphate and 4-hydroxybutyric acid (L) to the primary amino group (N) of a PNA-hexa-thymidylate (t)7 and alanine (Ala). Neither the synthesis of this compound nor any properties have been described.
(6) PNAs show highly cytotoxic properties in the molar range in cell culture experiments.

The orientation of the base-pairing nucleic acid strands is defined as follows: (cf. Egholm et al.; Nature 365 (1993) 566-568).

A) 5' ---------- 3' DNA ap Duplex ap = antiparallel 3' ---------- 5' DNA

B) 5' ---------- 3' DNA p Duplex p = parallel 5' ---------- 3' DNA

C) 5' ---------- 3' DNA ap Duplex (DNA=PNA) C ----------- N PNA

D) 5' ---------- 3' DNA p Duplex (DNA=PNA) N ----------- C PNA

E) C ----------- N PNA
5' ---------- 3' DNA (Pu) ap=ap triplex (DNA=DNA=PNA) 3' ---------- 5' DNA Pu = purine-rich strand F) N ----------- C PNA
5' ---------- 3' DNA (Pu) ap=p triplex (DNA=DNA=PNA) 3' ---------- 5' DNA

G) N ----------- C PNA
5' ---------- 3' DNA (Pu) ap=p triplex (PNA=DNA=PNA) C ----------- N PNA

H) C ----------- N PNA
5' ---------- 3' DNA (Pu) ap=ap triplex (PNA=DNA=PNA) C ----------- N' PNA

I) N ----------- C PNA
5' ---------- 3' DNA (Pu) p=p triplex (DNA=DNA=PNA) N ----------- C' PNA

K) C ----------- N PNA
5' ---------- 3' DNA (Pu) p=ap triplex (DNA=DNA=PNA) N ----------- C PNA

where 5' means the 5' end of an oligonucleotide, 3' means the 3' end of an oligonucleotide, N means the amino terminus of a PNA
C means the carboxyl terminus of a PNA.
Cases A)-D) are examples of the types of orientation which are possible in principle for the antisense oligo-mers. Cases E)-F) show possibilities for triplex forma-tion on single-stranded or double-stranded nucleic acids.
It is moreover possible for two of the PNA or DNA single strands to be linked together. For example, in E) the N terminus of the PNA can be linked to the 5' end of the DNA, or in F) the C terminus of the PNA can be linked to the 5' end of the DNA.

The object of the invention therefore was to prepare polyamide-oligonucleotide derivatives in which the abovementioned disadvantages are eliminated.

The invention relates to polyamide-oligonucleotide derivatives of the formula I

F[(DNA-Li)q(PNA-Li)r(DNA-Li)S(PNA)t],F' (I) wherein q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t > 2;
x is 1 to 20, preferably 1 to 5, particularly prefer-ably 1;
DNA is a nucleic acid such as DNA or RNA or a known derivative thereof;
Li is a covalent linkage between DNA and PNA, where the covalent linkage comprises a bond or an organic radical with at least one atom from the series consisting of C, N, 0 or S;
PNA is a polyamide structure which contains at least one nucleotide base which is different from thymine; and F and F' are end groups and/or are linked together by a covalent bond (cyclic compounds), and the physiologically tolerated salts thereof.
Particular mention may furthermore be made of polyamide-oligonucleotide derivatives of the formula I in which x is 1 and, at the same time, q = r = 1 and s = t= zero or r = s = 1 and q = t = zero or q = r = s = 1 and t = zero or r = s= t = 1 and q = zero.

Preferred compounds have the formulae Ia and Ib ( (NU)n 0 a CN2 R2 C=0 0 il (Lt~J (D). - CH2-CN2-N - CH= - C - (Li2J
T
(Nu)e 0 8 ~
CHI

R' C=0 0 (la) II
(Li~) (D)o - CHZ-CHZ-N - CHZ - C P' t ~
t F CH=-CHI-N -H2C - C - (0')p L( II
0=C 0 2 (Nu)e 1 t (Li~)-CNI-CN=-N -NtC - C - (D')~ --{li 11 i 0=C 0 N= (Ib) (Nu)~ I' r Q
in which x is 1 to 20, where when x > 1 r = s = 1 and, at the same time, q= t = zero and o = n= zero to 5;
q, r, s, t are, independently of one another, zero or 1, where the total of two or more adjacent q, r, s and t z 2;
R2 is hydrogen, hydroxyl, C1-C18-alkoxy, preferably C1-C6-alkoxy, halogen such as F or Cl, preferably F, azido or amino;
B is, independently of one another, a base customary in nucleotide chemistry, for example natural bases such as adenine, cytosine, thymine, guanine, uracil, inosine or unnatural bases such as, for example, purine, 2,6-diaminopurine, 7-deazaadenine, 7-deaza-guanine, N4,N4-ethanocytosine, N6,N6-ethano-2,6-di-aminopurine, pseudoisocytosine, 5-methylcytosine, 5-fluorouracil, 5-(C3-C6)-alkynyluracil, 5-(C3-C6)-alkynylcytosine or the prodrug forms thereof, and the "curved bracket" indicates that R2 and the adjacent substituent can be in the 2' position and 3' position or else conversely in the 3' position and 2' position;
Nu is a radical of the formulae IIa or IIb 5' 51 FR RZ
Y Y
I I
U P V U P V

II II
W yy (Ila) (Ilb) in which R2 and B are as defined above;
U is hydroxyl, mercapto, C1-C18-alkyl, preferably C1-C8-alkyl, C1-C16-alkoxy, preferably C1-C8-alkoxy, C6-C20-aryl, preferably C6-C12-aryl, C6-C14-aryl-C1-C8-alkyl, preferably C6-aryl-C1-Cq-alkyl, NHR3 or NR3R4, and R3 is C1-C18-alkyl or C1-Cq-alkoxy-C1-C4-alkyl, prefer-ably C1-C8-alkyl or C1-C4-alkoxy-C1-C4-alkyl, par-ticularly preferably C1-C4-alkyl or methoxyethyl and R4 is C1-C18-alkyl, preferably C1-C8-alkyl and particu-larly preferably C1-C4-alkyl, or R3 and R4 is, together with the nitrogen atom carrying them, a 5-6-membered heterocyclic ring which can additionally contain another hetero atom from the series consisting of 0, S, N, such as, for example, morpholine;
V is oxy, thio or imino;
W is oxo or thioxo;
Y is oxy, thio, methylene or imino;
m is zero to 20;
o is zero to 20;
D is a radical of the formula III
B

( 0 (III) I II

H
in which B is as defined above;
D' is a radical of the formula IV

H I I

0-C (IV) B
in which B is as defined above;
n is zero to 20;
p is zero to 20;
Lil, Li2, Li3 and Li4 are each, independently of one another, a structure of the formula V

[(V')-(G)-(G')]E (V) where, independently of one another, E is 1 to 5, preferably 1-2, V' is oxygen, NH, a bond or a radical of the formula VI
U
I
Y P V (VI) II
w in which U, V, W and Y are as defined above;
G can be C1-C12-alkanediyl, preferably C1-C6-alkane-diyl, where alkanediyl can optionally be substituted by halogen, preferably F or chlorine, amino, hydroxyl, C1-C18-alkyl, preferably C1-C6-alkyl, C1-C18-alkoxy, preferably C1-C6-alkoxy, C6-C14-aryl, preferably C6-aryl, or C6-C14-aryl-C1-C18-alkyl, preferably C6-aryl-C1-C4-alkyl; C6-C14-aryl-di-C1-C12-alkanediyl, preferably C6-aryl-di-C1-C4-alkane-diyl, or a group of the formula (CH2CH2O)SCH2CH2 in which b can be 1 to 11, preferably 1 to 7; or a bond; and G' is oxy, thio, imino, -C(O)-, -C(O)NH-, a bond or a radical of the formula VI in which U, V, W and Y are as defined above; and F and F' are linked by a bond (cyclic compounds) and/or F is R 0 - (A)Wk V and F' in formula Ia is -(Q) 1- R1 and in formula Ib is V1 - (A)1 - R1, where R is hydrogen, C1-C18-alkanoyl, preferably C8-C18-alkanoyl, C1-C18-alkoxycarbonyl, C3-C8-cycloalkanoyl, C7-C15-aroyl, C3-C13-heteroaroyl or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto the target nucleic acid, attacks the latter with binding, crosslinking or cleavage; or if k is zero, R is hydrogen or together with V is a radical of the formula VII

V
I
Z P Z(vii) (I
w in which Z and Z' are, independently of one another, hydroxyl, mercapto, C1-C22-alkoxy, preferably C12-C18-alkoxy, C1-C18-alkyl, preferably C12-C18-alkyl, C6-C20-aryl, preferably C6-C16-aryl, C6-C14-aryl-C1-C1e-alkyl, preferably C6-aryl-Cl-C4-alkyl, C1-C22-alkylthio, preferably C12-C18-alkylthio, NHR3, NR3R4, or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto the target nucleic acid, attacks the latter with binding, crosslinking or cleavage, and in which R3, R4, V and W are as defined above;
R1 is hydrogen or Q
where R1 is always only hydrogen when at the same time 1 is zero and in formula Ia t is zero and s is 1 and Lil is a structure of the for-mula V with V' = bond, G bond, E= 1 and G' = oxy, thio, imino or a radical of the formula VI with U = Z
or in formula Ib q is 1 or q r = zero and in F' = V1 -(A)1 - R1 with V1 = V, A and Q are, independently of one another, the residue of a natural or unnatural amino acid, pre-ferably from the series consisting of glycine, leucine, histidine, phenylalanine, cysteine, lysine, arginine, aspartic acid, glutamic acid, proline, tetrahydroisoquinoline-3-carboxylic acid, octahydro-indole-2-carboxylic acid, N-(2-aminoethyl)glycine;
Q is hydroxyl, OR', NH2, NHR" with R' = C1-C1e-alkyl, preferably C12-C18-alkyl and R" = C1-C18-alkyl, preferably C12-C18-alkyl, C1-C1e-aminoalkyl, preferably C12-C18-amino-alkyl, C1-C18-hydroxyalkyl, preferably C12-C18-hydroxyalkyl;
V is as defined above;
V1 is a bond or V, where in F' only in formula Ib with q = zero and r = 1 V1 is always a bond;
k is zero to 10;
1 is zero to 10;
with the proviso that a) if in the compound of the formula Ia t is zero and s is 1, and Lil is (V') - (G) -(G') with V' = a compound of the formula VI, G = C2-C12-alkylene and G' = CO, in F' _-(Q)1 - R1 1 is zero to 10 and R1 is Q ;
b) if in the compound of the formula Ia s = t = zero, Li2 is a bond;
c) if in the compound of the formula Ib t is zero and s is 1, Li3 is a bond;
d) if in the compound of the formula Ib s = t = zero, Li4 is a bond;

where each nucleotide can be in its D or L configuration, and the base can be in the a or Q position.

Particularly preferred compounds of the formula Ia and Ib are those in which the base is located on the sugar in the (3 position, x is 1 and q = r = 1, s= t = zero or r = s= 1, q = t = zero or q = r = s= 1, t = zero or r = s = t = 1, q = zero.

Especially preferred oligomers have the formulae Ia and Ib in which V', V, Y and W have the meaning of thio, oxy, oxo or hydroxyl; these are very particularly preferred if, in addition, R2 is hydrogen.

Also especially preferred are oligomers of the formulae Ia and Ib with E= 1, in which Lil, Li4 are a) a compound of the formula V in which V' = oxygen or compound of the formula VI, G = C1-Clp-alkylene, G' = -CONH-b) a compound of the formula V in which G, V.
is a bond and G' is a compound of the formula VI with, preferably, U = V = W = Y = oxygen or U = W = Y = oxygen and V = imino Li2, Li3 are a) a compound of the formula V with V' = imino, G = C1-C10-alkylene and G' = compound of the formula VI
b) a compound of the formula V with V' = imino, G and G' = bond c) a compound of the formula V with V' = imino, G = C1-Clo-alkylene and G' = V with, prefer-ably, U = V = W = Y = oxygen.

Very particularly preferred oligomers have the formulae Ia and Ib in which V' , V, Y and W have the meaning of thio, oxy, oxo or hydroxyl, R2 is hydrogen, Lil has the meaning of -V'-[CH2]nC(O)NH- with V' = compound of the formula VI with U = V = W = Y = oxygen or Li2 has the meaning of -HN-[CH2]n(G')-, where n is 2 to 5 and G' has the formula VI with U, V, W and Y = oxygen.

Additionally preferred oligomers of the formulae Ia and Ib are those in which V', V, Y and W have the meaning of thio, oxy, oxo or hydroxyl, R2 is hydrogen, Lil has the meaning of -O-[CH2]õC(O)NH- or Li2 has the meaning of -HN-[CH2]n(G')-, where n is 2 to 5 and G' has the formula VI with U, V, W and Y = oxygen, and q = zero and r= s= t= 1.

Additionally preferred are oligomers of the formulae Ia and Ib in which the curved bracket means that R2 is in the 3' position (see formula Iib). The preferred base in this case is adenine.

The invention is not confined to a- and R-D- and L-ribo-furanosides, a- and Q-D- and L-deoxyribofuranosides and corresponding carbocyclic five-membered ring analogs but also applies to oligonucleotide analogs which are com-posed of different sugar building blocks, for example ring-expanded and ring-contracted sugars, acyclic, ring-bridged or other suitable types of sugar derivatives. The invention is furthermore not confined to the derivatives, indicated by way of example in formula I, of the phos-phate residue but also relates to known dephospho derivatives.

The oligonucleotide part (DNA in formula I) can therefore be modified from the natural structure in a wide variety of ways. Examples of such modifications, which are introduced by methods known per se, are:

a) Modifications of the phosphate bridge Examples which may be mentioned are: phosphorothioates, phosphorodithioates, methylphosphonates, phosphor-amidates, boranophosphates, phosphate methyl esters, phosphate ethyl esters, phenylphosphonates. Preferred modifications of the phosphate bridge are phosphorothio-ates, phosphorodithioates and methylphosphonates.

b) Replacement of the phosphate bridge Examples which may be mentioned are: replacement by formacetal, 3'-thioformacetal, methylhydroxylamine, oxime, methylenedimethylhydrazo, dimethylene sulfone, silyl groups. Replacement by formacetals and 3'-thio-formacetals is preferred.

c) Modifications of the sugar Examples which may be mentioned are: a-anomeric sugars, 2'-O-methylribose, 2'-O-butylribose, 2'-O-allylribose, 2'-fluoro-2'-deoxyribose, 2'-amino-2'-deoxyribose, a-arabinofuranose, carbocyclic sugar analogs. The pre-ferred modification is that by 2'-O-methylribose and 2'-O-n-butylribose.

d) Modifications of the bases with do not alter the specificity of the Watson-Crick base pairing Examples which may be mentioned are: 5-propynyl-2'-deoxy-uridine, 5-propynyl-2'-deoxycytidine, 5-hexynyl-2'-deoxy-uridine, 5-hexynyl-2'-deoxycytidine, 5-fluoro-2'-deoxy-cytidine, 5-fluoro-2'-deoxyuridine, 5-hydroxymethyl-2'-deoxyuridine, 5-methyl-2'-deoxycytidine, 5-bromo-2'-deoxycytidine. Preferred modifications are 5-propynyl-2'-deoxyuridine, 5-hexynyl-2'-deoxyuridine, 5-hexynyl-2'-deoxycytidine and 5-propynyl-2'-deoxycytidine.

e) 3'-3' and 5'-5' inversions [for example M. Koga et al., J. Org. Chem. 56 (1991) 3757]

f) 5'- and 3'-phosphates, and 5'- and 3'-thiophosphates.
Examples of groups which favor intracellular uptake are various lipophilic radicals such as -O-(CH2),-CH3 in which x is an integer from 6 to 18, -0-(CH2)n-CH=CH-(CH2)m CH3 in which n and m are, independently of one another, an integer from 6 to 12, -O-(CH2CH2O)q-(CH2)9-CHg, -O-(CH2CH2O)8-(CH2)13-CH3 and -O-(CH2CH2O)7-(CH2)15-CH3, but also steroid residues such as cholesteryl or vitamin residues such as vitamin E, vitamin A or vitamin D and other conjugates which utilize natural carrier systems such as bile acid, folic acid, 2-(N-alkyl-N-alkoxyamino)-anthraquinone and conjugates of mannose and peptides of the appropriate receptors which lead to receptor-mediated endocytosis of the oligonucleotides, such as EGF
(Epidermal Growth Factor), bradykinin and PDGF (Platelet Derived Growth Factor). By labeling groups are meant fluorescent groups, for example of dansyl (= 1-dimethyl-aminonaphthalene-5-sulfonyl), fluorescein or coumarin derivatives or chemiluminescent groups, for example of acridine derivatives, and the digoxigenin system detect-able by ELISA, the biotin group detectable by the biotin/avidin system or else linker arms with functional groups which permit subsequent derivatization with detectable reporter groups, for example an aminoalkyl linker which is reacted with an acridinium active ester to give the chemiluminescence probe. Typical labeling groups are:

H COOH
I

~0 Fluorescein derivative CHs N( ' 0 N-(CH=)1-N-H H
Acridinium ester 0 0-(CHI)=-0-.
\ \ I ~

C 0 0 R x- 2-18 Drelerabiy 4 R = H or C,-C4-aikyl i (= 'rluorescein' for x 4 and R = CH3 ) Fluorescein derivative 0 R = H or amino protective group R - N N H
H

Is Biotin conjugate (_ "Biotin" for R = Fmoc ) \

OH

-H
Digoxigenin conjugate Oligonucleotide analogs which bind to or intercalate and/or cleave or crosslink nucleic acids contain, for example, acridine, psoralen, phenanthridine, naphtho-quinone, daunomycin or chloroethylaminoaryl conjugates.
Typical intercalating and crosslinking radicals are:
-0-(CH2 ), iN

Acridine derivative x = 2-12, preferably 4 OCH~

/ \
-S - (CHZ)-NH N

CI
x = 2-12, preferably 4 CH2X-(CH2)2-NH-C-~
~
11 0 0 C H X - -NH or -0-CH~
Trimethylpsorolene conjugate (- "psoralene" tor z-0) NH

N
N
Phenonihroline conjugote HN

O

Psoralen conjugate NH,,~/0-~
CI

Nophthoquinone conjugote OH
N.

CHj NH
~

Daunomycin derivative C I -CH2CH2\
N ( CHZ ) x-0-X

:= 1-18, X- Alkyl, Holoyen, NO2, CN, -C-R

C I -CHZCHZ\
/ N (CHZ),-0-CI-CH2CHz x x- I-18, X- Alkyl, Holoflen, NOq, CN, -C-R
I ) Examples which may be mentioned of NR3R4 groups in which R3 and R4 form, together with the nitrogen atom carrying them, a 5- to 6-membered heterocyclic ring which addi-tionally contains another hetero atom are the morpholinyl and the imidazolidinyl radical.

The polyamide part (PNA in formula I) is composed of amide structures which contain at least one nucleotide base which is different from thymine. Polyamide struc-tures of this type are composed, for example, of the following building blocks a) to h), preferably a), in which f is 1 to 4, preferably 1 or 2 and g is zero to 3, preferably zero to 2:

a) B
CHI
C=0 NH-(CH2)f-CH2-N-(CH1)f-CO

Hyrup et al.; J. Chem. Soc. Chem. Comm. 1993, 519 b) B
(CHz)~
I

De Konig et al. (1971) Rec. Trav. Chim. 91, 1069 c) B
I
C Hz)r (i NH-CH-CHi-CH2-CHi-CO
Huang et al. (1991) J. Org. Chem. 56, 6007 d) B
I
(CH2 ) f N H- C H z-C O-N-C H z-C O

Almarsson et al. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, e) B

C=0 Froehler et al. (1991) WO 93/10820 f) B

C H
NH-CH2-CH2-N_,,~ CO

Froehler et al. (1991) WO 93/10820 g) B
( i H 2 ) i NH-CH-CO-N~
CO
Lewis (1993) Tetrahedron Lett. 34, 5697.
h) ~N,r( C H 2 cO
( C H 2 ) f NH-(CH2)q End groups for PNAs are described in the applications, filed simultaneously, with the titles "PNA synthesis using an amino protective group which is labile to weak acids" (HOE 94/F 060, DE-P 44 08 531.1) and "PNA syn-thesis using a base-labile amino protective group"
(HOE 94/F 059, DE-P 44 08 533.8).
Preferred polyamide structures are composed of structures according to a). The latter are particularly preferred when f is 1.

The preparation of polyamide-oligonucleotide derivatives of the formula I takes place similarly to the synthesis of oligonucleotides in solution or, preferably, on solid phase, where appropriate with the assistance of an automatic synthesizer. The oligomer of the formula I can be assembled stepwise by successive condensation of one PNA unit or DNA unit with in each case one nucleotide base onto an appropriately derivatized support or onto a growing oligomer chain. However, the assembly can also take place in fragment fashion, in which case the frag-ments are first synthesized as polyamide or oligonucleo-tide structures which are then linked to give the polyamide-oligonucleotide of the formula I. However, it is also possible to use building blocks composed of PNA
and nucleotide, preferably dimers, which are then assembled by the methods of nucleotide chemistry or peptide chemistry to give polyamide-oligonucleotide derivatives.

The assembly of the oligonucleotide part takes place by processes known to the skilled worker, such as the triester method, the H-phosphonate method or phosphor-amidite method, preferably by the standard phosphor-amidite chemistry of Caruthers (M.D. Matteucci and M.H. Caruthers, J. Am. Chem. Soc. 103, 3185 (1981)). The polyamide part can be synthesized by the methods of peptide chemistry known to the skilled worker. If the oligonucleotide part and polyamide part are not sepa-rately synthesized and subsequently linked, the processes used to assemble the oligonucleotide structure and polyamide structure must be mutually compatible, in which connection a preferred embodiment of the synthesis of the polyamide part is described in the simultaneously filed application with the title "PNA synthesis using an amino protective group which is labile to weak acids"
(HOE 94/F 060, DE-P 44 08 531.1).

Depending on whether q, r, s and t are 1 or zero, the synthesis starts with the oligonucleotide part or with the polyamide part. The synthesis of compounds of the formula I whose oligonucleotide part is modified at the 3' and/or at the 5' end takes place in respect of these modifications by the processes described in EP-A 0 552 766 (HOE 92/F 012) (compare synthetic scheme for DNA). The synthesis of compounds of the formula I
takes place in respect of the polyamide part by the process described in the simultaneously filed application with the title "PNA synthesis using an amino protective group which is labile to weak acids (HOE 94/F 060, DE-P
44 08 531.1) (compare synthetic scheme for PNA).

Synthetic scheme for DNA
[anchor group]-[polymer]
1. 1 coupling on of PG-(Nu')-active PG-(Nu')-[anchor group]-[polymer]
2. 1 elimination of protective group PG
H-(Nu')-[anchor group]-[polymer]
3. 1 repetition of steps 1 and 2(n-1) times H-(Nu')n-[anchor group]-[polymer]
4. 1 coupling on of R -V-active R0-V-(Nu')n-[anchor group]-[polymer]
5. 1 elimination of polymer and protective groups RO-V-(Nu)n Synthetic scheme for PNA
[anchor group]-[polymer]
1. 1 coupling on of PG-(Q')-OH
PG-(Q')-[anchor group]-[polymer]
2. 1 elimination of protective group PG
H-(Q')-[anchor group]-[polymer]
3. 1 repetition of steps 1 and 2 (1-1) times H-(Q')1-[anchor group]-[polymer]
4. 1 coupling on of PG-[B'/X]-OH
PG-[B'/X]-(Q')1-[anchor group]-[polymer]
5. 1 elimination of protective group PG
H-[B'/X]-(Q')1-[anchor group]-[polymer]
6. 1 repetition of steps 4 and 5(n-1) times H-[B'/X]n-(Q')1-[anchor group]-[polymer]
7. 1 coupling on of PG-(A')-OH
PG-(A')-[B'/X]n-(Q')1-[anchor group]-[polymer]
8. 1 elimination of protective group PG
H-(A')-[B'/X]n-(Q')1-[anchor group]-[polymer]
9. 1 repetition of steps 7 and 8(k-1) times H-(A')k-[B'/X]n-(Q')1-[anchor group]-[polymer]
10. 1 coupling on of the group R
R -(A')k-[B'/X]n-(Q')1-[anchor group]-[Polymer]
11. 1 elimination of polymer and protective groups R0-(A)k-[B/X]n-(Q)1-Qo The meanings in this are:
PG protective group, preferably a protective group labile to weak acid;
Nu' nucleotide unit whose exocyclic amino group is pro-tected by a suitable protective group;
Nu'-active an activated derivative customary in nucleotide chemistry, such as, for example, of a phos-phoramidite, a phosphodiester or an H-phosphonate;
A', B' and Q' are the forms of A, B and Q which are protected where appropriate.

Synthetic scheme for PNA/DNA hybrids of the formula I
F[(DNA-Li)q(PNA-Li)=(DNA-Li)5(PNA)t],F' (I) For q = r = s = t = 1 and x = 1, the following outline of the synthesis applies:

1. 1 synthesis of the end group F'; where appro-priate conjugation to polymer PG-F' 2. 1 elimination of protective group PG
H-F' 3. 1 conjugation of the polyamide structure PNA-F' 4. 1 coupling on of a linker Li-PNA-F' 5. 1 conjugation of the nucleotide structure DNA-Li-PNA-F' 6. 1 coupling on of a linker Li-DNA-Li-PNA-F' 7. 1 repetition of steps 3 to 5 DNA-Li-PNA-Li-DNA-Li-PNA-F' 8. 1 coupling on of the end group F
F-DNA-Li-PNA-Li-DNA-Li-PNA-F' The coupling on of the linker building block can be omitted if appropriate junctions are present in the PNA
or DNA building blocks.

For clarification, a synthetic scheme for PNA/DNA
hybrids of the formula I is shown and explains by way of example the preparation of a hybrid oligomer in which q = r = s = t = 1 and x = 1. Initially, the end group F
is synthesized by known processes and, in the case of solid-phase synthesis, coupled to a polymeric support (step 1). After elimination of the protective group PG
(step 2), which preferably takes place in weakly acidic medium, the polyamide building blocks are coupled on to the desired length of the PNA part (step 3). As junction to the DNA part it is now possible to attach a linker unit (step 4). The conjugation of the nucleotide struc-ture then takes place by successive condensation on of the nucleotide building blocks (step 5), preferably by the known phosphoramidite method. After a linker which makes it possible to join DNA to PNA has been condensed on (step 6), in turn a polyamide structure is assembled.
Introduction of a linker which makes it possible to join PNA to DNA, conjugation of another DNA structure (step 7) and final coupling on of the end group F (step 8) result in the hybrid molecule [F-DNA-Li-PNA-Li-DNA-Li-PNA-F'].
The linker building blocks can in this case also contain nucleotide bases. To synthesize a hybrid F-DNA-Li-PNA-Li-F' (q = r = 1, s = t = zero), for example first steps 1-5 are carried out and then the synthesis is completed with step 8.

To synthesize a hybrid F-PNA-Li-DNA-F' (r = s = 1, q = t = zero), for example first steps 1-2 are carried out, then steps 5-6 follow, followed by step 3 and completion of the synthesis with step 8.

To synthesize a hybrid F-PNA-Li-DNA-Li-PNA-F' (r = s = t = 1, q = zero), the synthesis starts with steps 1-6. After repetition of step 3, the synthesis is completed with step 8.

If x in formula I is > 1, then steps 2-7 must be repeated where appropriate. After assembly of the polymeric chains, the PNA/DNA hybrids must in the case of solid-phase synthesis be cleaved off the support and, where appropriate, the protective groups on the bases, amino-acid side chains and end groups must be eliminated.
However, the PNA part and DNA part can also be synthesized separately by known methods and subsequently coupled together via appropriate activation of at least one component. Activation of the PNA part preferably takes place via the carboxylic acid group, for example as active ester or isothiocyanate, which are then reacted with reactive groups in the DNA part, preferably an amino group. Activation of the DNA part takes place, for example, in the form of a cyanogen bromide condensation known per se, in which the activated phosphate functionality is reacted with a reactive group in the PNA
part, preferably an amino group.

It has been found, surprisingly, that the oligomers of the formula Ia and Ib have a greatly increased cellular uptake by comparison with pure PNAs. This improved cellular uptake is very crucial because antisense- or triplex-forming oligomers are able to act only if they are efficiently taken up by cells. Their hybridization behavior is likewise more favorable than in the case of pure PNAs because they preferentially lead to anti-parallel duplex formation. Compared with normal oligonucleotides, they have an improved nuclease stabi-lity, which is expressed by an increased biological activity. The binding affinity to complementary nucleic acids is better than the other nuclease-stable oligo-nucleotides such as, for example, phosphorothioates or methylphosphonates. The binding affinity of the compounds according to the invention is at least equally good, but usually better, by comparison with natural oligonucleo-tides, which are rapidly degraded under serum conditions.
The increase in the binding affinity depends on the length of the PNA part. Pure PNAs showed a potent cytotoxic effect at concentrations > 5 M in cell-culture experiments, whereas the compounds according to the invention did not damage the cells. It has furthermore been found that compounds of the formula I inhibit, depending on the base sequence of the PNA part and DNA
part, the expression of specific genes, for example of enzymes, receptors or growth factors, in cell culture and in selected examples in animal models.

Further advantages of the PNA/DNA oligomers and PNA/RNA
oligomers comprise the possibility of stimulating cellular endonucleases such as, for example, RNase H and RNase L. In contrast to PNAs, the PNA-DNA chimeras according to the invention which have some deoxyribo-nucleotide units are able, after binding to the comple-mentary target RNA, to cleave the latter in a sequence-specific manner owing to induction of cellular RNase H.
A particular embodiment of the oligomers according to the invention furthermore comprises those which are composed of PNA part and a 2',5'-linked oligoadenylate part, preferably tetraadenylate or its cordycepin analog, and which activate cellular RNase L.
The present invention extends very generally to the use of compounds of the formula I as therapeutically active ingredients of a pharmaceutical. By therapeutically active polyamide-oligonucleotide derivatives is meant in general antisense oligonucleotides, triple helix-forming oligonucleotides, aptamers or ribozymes, especially antisense oligonucleotides.

The pharmaceuticals of the present invention can be used, for example, to treat diseases caused by viruses, for example by HIV, HSV-1, HSV-2, influenza, VSV, hepatitis B or papilloma viruses.

Antisense polyamide-oligonucleotide derivatives according to the invention which are active against such targets have, for example, the following base sequence. The length and position of the PNA part and DNA part in these sequences can be altered appropriately to achieve optimal properties.

a) against HIV, for example 5'-A C A C C C A A T T C T G A A A A T G G-3 ' or (I) 5'-A G G T C C C T G T T C G G G C G C C A-3' or (II) 5'-G T C G A C A C C C A A T T C T G A A A A T G G A T A A-3 ' or (III) 5'-G C T A T G T C G A C A C C C A A T T C T G A A A-3' or (IV) 5'-T C G T C G C T G T C T C C G C T T C T T C T T C C T G C C A or (VI) b) against HSV-1, for example 5'-G C G G G G C T C C A T G G G G G T C G-3 ' (VII) The pharmaceuticals of the present invention are also suitable, for example, for the treatment of cancer. In this connection, it is possible to use, for example, polyamide-oligonucleotide sequences which are directed against targets which are responsible for the development of cancer or the growth of cancers. Examples of such targets are:

1) nuclear oncoproteins such as, for example, c-myc, N-myc, c-myb, c-fos, c-fos/jun, PCNA, p120 2) cytoplasmic/membrane-associated oncoproteins such as, for example, EJ-ras, c-Ha-ras, N-ras, rrg, bcl-2, cdc-2, c-raf-1, c-mos, c-src, c-abl 3) cellular receptors such as, for example, the EGF
receptor, c-erbA, retinoid receptors, protein kinase regulatory subunit, c-fms 4) cytokines, growth factors, extracellular matrix such as, for example, CSF-1, IL-6, IL-la, IL-lb, IL-2, IL-4, bFGF, myeloblastin, fibronectin.

Antisense polyamide-oligonucleotides of the formula I
according to the invention which are active against such targets have, for example, the following base sequence:
a) against c-Ha-ras, for example 5'-C A G C T G C A A C C C A G C-3' (VIII) c) c-myc, for example 5'-G G C T G C T G G A G C G G G G C A C A C-3' (IX) 5'-A A C G T T G A G G G G C A T-3' (X) d) c-myb, for example 5'-G T G C C G G G G T C T T C G G G C-3 ' (XI) e) c-fos, for example 5'-G G A G A A C A T C A T G G T C G A A A G-3 ' (XII) 5'-C C C G A G A A C A T C A T G G T C G A A G-3' (XIII) 5'-G G G G A A A G C C C G G C A A G G G G-3 (XIV) f) p120, for example 5'-C A C C C G C C T T G G C C T C C C A C-3' (XV) g) EGF receptor, for example 5'-G G G A C T C C G G C G C A G C G C-3 ' (XVI) 5'-G G C A A A C T T T C T T T T C C T C C-3 (XVII) h) p53 tumor suppressor, for example 5'-G G G A A G G A G G A G G A T G A G G-3' (XVIII) 5'-G G C A G T C A T C C A G C T T C G G A G-3'r (XIX) The pharmaceuticals of the present invention are further-more suitable, for example, for the treatment of diseases which are influenced by integrins or cell-cell adhesion receptors, for example by VLA-4, VLA-2, ICAM, VCAM or ELAM.

Antisense polyamide-oligonucleotide derivatives according to the invention which are active against such targets have, for example, the following base sequence:

a) VLA-4, for example 5'-G C A G T A A G C A T C C A T A T C-3' or (XX) b) ICAM, for example 5'-C C C C C A C C A C T T C C C C T C T C-3' (XXI) 5'-C T C C C C C A C C A C T T C C C C T C-3 ' (XXII) 5'-G C T G G G A G C C A T A G C G A G G-3' (XXIII) c) ELAM-1, for example 5'-A C T G C T G C C T C T T G T C T C A G G-3' (XXIV) 5'-C A A T C A A T G A C T T C A A G A G T T C-3' (XXV) The pharmaceuticals of the present invention are also suitable, for example, for preventing restenosis. In this connection, examples of polyamide-oligonucleotide sequences which can be used are those directed against targets which are responsible for proliferation or migration. Examples of such targets are:
1) nuclear transactivator proteins and cyclins such as, for example, c-myc, c-myb, c-fos, c-fos/jun, cyclins and cdc2 kinase 2) mitogens or growth factors such as, for example, PDGF, bFGF, EGF, HB-EGF and TGF-R

3) cellular receptors such as, for example, bFGF recep-tor, EGF receptor and PDGF receptor.

Antisense polyamide-oligonucleotides according to the invention of the formula I which are active against such targets have, for example, the following base sequence:
a) c-myb 5'-G T G T C G G G G T C T C C G G G C-3' (XXVI) b) c-myc 5'-C A C G T T G A G G G G C A T-3' (XXVII) c) cdc2 kinase 5'-G T C T T C C A T A G T T A C T C A-3 ' (XXVIII) d) PCNA (proliferating cell nuclear antigen of rat) 5'-G A T C A G G C G T G C C T C A A A-3 ' (XXIX) The pharmaceuticals can be used, for example, in the form of pharmaceutical products which can be administered orally, for example in the form of tablets, coated tablets, hard or soft gelatin capsules, solutions, emul-sions or suspensions. Inclusion of the pharmaceuticals in liposomes, which optionally contain further components such as proteins, is a likewise suitable administration form. They can also be administered rectally, for example in the form of suppositories, or parenterally, for example in the form of injection solutions. To produce pharmaceutical products, these compounds can be processed in therapeutically inert organic and inorganic exci-pients. Examples of such excipients for tablets, coated tablets and hard gelatin capsules are lactose, corn starch or derivatives thereof, talc and stearic acid or salts thereof. Suitable excipients for producing solutions are water, polyols, sucrose, invert sugar and glucose. Suitable excipients for injection solutions are water, alcohols, polyols, glycerol and vegetable oils.
Suitable excipients for suppositories are vegetable and hardened oils, waxes, fats and semiliquid polyols. The pharmaceutical products may also contain preservatives, solvents, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavorings, salts to alter the osmotic pressure, buffers, coating agents, antioxidants and, where appropriate, other therapeutic active substances.

Preferred administration forms are topical applications, local applications such as, for example, with the aid of a catheter or else injections. For injection, the antisense polyamide-oligonucleotide derivatives are formulated in a liquid solution, preferably in a physio-logically acceptable buffer such as, for example, Hank's solution or Ringer's solution. The antisense polyamide-oligonucleotides can, however, also be formulated in solid form and be dissolved or suspended before use. The dosages preferred for systemic administration are about 0.01 mg/kg to about 50 mg/kg of body weight and day.
The invention extends very generally to the use of compounds of the formula I as DNA probes or primers in DNA diagnosis, in particular in the sense of the gene probes mentioned in HOE 92/F 406 (EP-A 0 602 524), and generally as aids in molecular biology.
Gene probes, also called DNA probes or hybridization probes, play a large part in DNA diagnosis for sequence-specific detection of particular genes. A gene probe is generally composed of a recognition sequence and of a suitable labeling group (label). The specificity of the determination of a target sequence in an analytical sample by hybridization with a complementary gene probe is determined by the recognition sequence and its chemi-cal structure. The PNAs have the advantage, compared with oligonucleotides of natural structure, that they have a higher affinity for the target sequence. However, the specificity of the hybridization is reduced because PNAs, in contrast to natural DNA, are able to bind both in parallel and in antiparallel orientation to single-stranded nucleic acids. The PNA/DNA oligomers according to the invention likewise show an increased binding affinity but very preferentially bind in the desired antiparallel orientation.

It is moreover possible, by appropriate selection of the PNA part and DNA part in a gene probe, to have a bene-ficial effect on the differentiation capacity because base mispairing in the PNA part leads to a greater depression of the melting temperature of a hybrid than does a base mispairing in the DNA part. This is particu-larly important with regard to differentiation in the case of point mutations as occur, for example, in the transition from protooncogenes into the corresponding oncogenes (pathogenic state). The advantage of the better discrimination between pathogenic and non-pathogenic state can also be utilized in the form of the primer pro-perty of the PNA/DNA oligomers according to the invention as long as these have a free 3'-hydroxyl group in the DNA
part. PNAs as such have no primer function for poly-merases. It has been found, surprisingly, that even one nucleoside unit at the end of a PNA/DNA oligomer is sufficient to initiate the DNA polymerase reaction, for example with DNA polymerase (Klenow fragment). Various polymerases can be employed depending on the characteris-tics of the PNA/DNA primer and the nature of the template onto which the primer hybridizes in a sequence-specific manner. These polymerases are generally commercially available, such as, for example, Taq polymerase, Rlenow polymerase or reverse transcriptase.

Another advantage by comparison with the use of natural oligonucleotide primers is that the nucleic acid strand which is copied with the aid of the PNA/DNA primer and which contains the PNA part at the 5' end is stable to 5'-exonucleases. It is thus possible to degrade all natural DNA or RNA sequences in the reaction mixture by 5'-exonucleases without attack on the PNA-containing strand.

Another advantage of the PNA/DNA oligomers is that they can also be used to carry out other biochemical reactions on the DNA part which are impossible with PNAs them-selves. Examples of such reactions are the 3'-tailing with 3'-terminal transferase, the digestion with restric-tion enzymes in the DNA double-stranded region, and ligase reactions. For example, a (PNA)-(DNA)-OH oligomer with free 3'-hydroxyl group can be linked to a second p-(DNA)-(PNA) oligomer which contains a nucleoside 5'-phosphate at the 5' end after hybridization to a complementary DNA auxiliary sequence of natural origin in the presence of a DNA ligase.

(DNA)-(PNA)-(DNA) oligomers can furthermore be incorpora-ted into genes, which is not at present possible with PNAs.

The linkage of labeling groups onto PNA/DNA oligomers takes place by methods known per se, as described for oligonucleotides or peptides. The nature of the labeling group can vary within wide limits and depends essentially on the type of assay used. Known embodiments of gene probe assays are the hybridization protection assay, the energy transfer assay and the kissing probes assay.
PNA/DNA oligomers are additionally particularly suitable for a strand displacement assay. In many cases it is advantageous to remove the hybrid which is formed from excess gene probe with the aid of magnetic particles. The stability of the PNA/DNA gene probes according to the invention is higher than that of conventional DNA probes.
Polymerase chain reaction (PCR) and ligase chain reaction (LCR) are techniques for target amplification in which the oligomers according to the invention can likewise be used as primers. The PNA/DNA oligomers can be used par-ticularly advantageously as gene probes on the Christmas tree principle because in this case the PNA/DNA probes can be shorter than corresponding DNA probes.

Examples:
The abbreviations used for amino acids correspond to the three-letter code customary in peptide chemistry, as described in Europ. J. Biochem. 138, 9 (1984). Other abbreviations used are listed below.
Aeg N-(2-Aminoethyl)glycyl, Aeg (aMeosz ) N- (2-Aminoethyl) -N- (N6- ( 4-methoxybenzoyl ) -9-adenosylacetyl)-glycyl Aeg(cBz) N-(2-Aminoethyl)-N-(N4-benzoyl-l-cytosyl-acetyl)-glycyl Aeg(cMeosz) N-(2-Aminoethyl)-N-(N4-(4-methoxybenzoyl)-1-cytosylacetyl)-glycyl Aeg ( ctB"Bz ) N- ( 2 -Aminoethyl ) -N- ( N4 - ( 4 -tert . butyl -benzoyl)-1-cytosylacetyl)-glycyl Aeg(gl$u) N- ( 2-Aminoethyl ) -N- (N2 -isobutanoyl-9-guanosylacetyl)-glycyl Aeg (g2-Ac, 4-np ) N- (2-Aminoethyl) -N- (N2-acetyl-04-diphenyl-carbamoyl-9-guanosyl)glycyl Aeg(t) N-(2-Aminoethyl)-N-((1-thyminyl)acetyl)-glycyl Bnpeoc 2,2-[bis(4-Nitrophenyl)]-ethoxycarbonyl) Boc tert.-butyloxycarbonyl BOI 2-(Benzotriazol-l-yloxy)-1,3-dimethyl-imidazolidinium hexafluorophosphate BOP Benzotriazolyl-l-oxy-tris(dimethylamino)-phosphonium hexafluorophosphate BroP Bromo-tris(dimethylamino)phosphonium hexafluorophosphate BSA N,O-bis(Trimethylsilyl)-acetamide But tert.-butyl Bz Benzoyl Bzl Benzyl C1-Z 4-Chloro-benzyloxycarbonyl CPG Controlled pore glass DBU 1,8-Diazabicyclo[5.4.0]undec-7-ene DCM Dichloromethane Ddz 2-(3,5-Dimethoxyphenyl)-2-propyloxycar -bonyl DMF Dimethylformamide Dmt di-(4-Methoxyphenyl)phenylmethyl Dnpeoc 2-(2,4-Dinitrophenyl)-ethoxycarbonyl Dpc Diphenylcarbamoyl FAM Fluorescein.residue Fm 9-Fluorenylmethyl Fmoc 9-Fluorenylmethyloxycarbonyl H-Aeg-OH N-(2-Aminoethyl)glycine HAPyU O-(7-Azabenzotriazol-l-yl)-1,1,3,3-bis -(tetramethylene)uronium hexafluorophos-phate HATU O-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetra-methyluronium hexafluorophosphate HBTU O-(Benzotriazol-1-yl)-1,1,3,3-tetra-methyluronium hexafluorophosphate HOBt 1-Hydroxybenzotriazole HONSu N-Hydroxysuccinimide HOObt 3-Hydroxy-4-oxo-3,4-dihydrobenzotriazine iBu Isobutanoyl MeOBz 4-Methoxybenzoyl Mmt 4-Methoxytriphenylmethyl Moz 4-Methoxybenzyloxycarbonyl MSNT 2-Mesitylenesulfonyl-3-nitro-1,2,4-tria-zole Mtt (4-Methylphenyl)diphenylmethyl NBA Nitrobenzyl alcohol NMP N-Methylpyrrolidine Obg N-(4-Oxybutyl)glycyl, -O-(CH2)4-NH-CH2-CO-Obg(t) N-(4-Oxybutyl)-N-((1-thyminyl)acetyl)-glycyl Oeg N-(2-Oxyethyl)glycyl, oeg(t) N-(2-Oxyethyl)-N-((i-thyminyl)acetyl)-glycyl Opeg N-(5-Oxypentyl)glycyl, -O-(CH2)5-NH-CH2-CO-opeg(t) N-(5-Oxypentyl)-N-((1-thyminyl)acetyl)-glycyl Oprg N-(3-Oxypropyl)glycyl, -0-(CH2)3-NH-CH2-CO-Oprg(t) N-(3-Oxypropyl)-N-((1-thyminyl)acetyl) -glycyl Pixyl 9-(9-Phenyl)xanthenyl PyBOP Benzotriazolyl-l-oxytripyrrolidinophos -phonium hexafluorophosphate PyBroP Bromotripyrrolidinophosphonium hexa-fluorophosphate TAPipU 0-(7-Azabenzotriazol-1-yl)-1,1,3,3-bis-(pentamethylene)uronium tetrafluoroborate TBTU 0-(Benzotriazol-1-yl)-1,1,3,3-tetra-methyluronium tetrafluoroborate tBu tert.-Butyl tBuBz 4-tert.Butylbenzoyl TDBTU O-(3,4-Dihydro-4-oxo-1,2,3-benzotriazin-3-yl)-1,1,3,3-tetramethyluronium tetra-fluoroborate TDO 2,5-Diphenyl-2,3-dihydro-3-oxo-4-hydroxy-thiophene dioxide Teg N-(2-Thioethyl)glycyl, Teg(t) N-(2-Thioethyl)-N-((1-thyminyl)acetyl) -glycyl TFA Trifluoroacetic acid THF Tetrahydrofuran TNTU O-(5-Norbornene-2,3-dicarboximido)-1,1,3,3-tetramethyluronium tetrafluoro-borate TOTU O-[(Cyano(ethoxycarbonyl)methylene)-amino]-1,1,3,3-tetramethyluronium tetra-fluoroborate TPTU O-(1,2-Dihydro-2-oxo-l-pyridyl)-1,1,3,3-tetramethyluronium tetrafluoroborate Trt Trityl TSTU O-(N-Succinimidyl)-1,1,3,3-tetramethyl-uronium tetrafluoroborate Z Benzyloxycarbonyl MS(ES+) Electrospray mass spectrum (positive ion) MS(ES ) Electrospray mass spectrum (negative ion) MS(DCI) Desorption chemical ionization mass spectrum MS(FAB) Fast atom bombardment mass spectrum Example 1 1-Hydroxy-6-((4-methoxyphenyl)-diphenylmethylamino)-hexane Mmt-hex 6-Amino-1-hexanol (1 g; 8.55 mmol) is dissolved in anhydrous pyridine (7 ml), and triethylamine (0.2 ml) is added. To this solution is added over the course of 45 minutes a solution of (4-methoxyphenyl)diphenylmethyl chloride (2.5 g; 8.12 mmol) in anhydrous pyridine (9 ml).
The reaction solution is stirred further at 22 C for 30 minutes and stopped by adding methanol (3 ml). The solution is concentrated in a rotary evaporator, and the resulting residue is coevaporated with toluene three times to remove the pyridine. The resulting residue is dissolved in ethyl acetate, and this solution is washed successively with a saturated sodium bicarbonate solu-tion, with water and with a saturated potassium chloride solution. The organic phase is dried (Na2SO4), filtered and concentrated in vacuo. The crude product is purified by silica gel chromatography using heptane:ethyl acetate:
triethylamine/49.5:49.5:1.
Yield: 1.64 g MS (FAB,NBA/LiCl) 396.3 (M + Li)+, 390.3 (M + H)+, 273.2 (Mmt)+

Rf 0.44 (heptane:ethyl acetate = 1:1) Example 2 6-((4-Methoxyphenyl)diphenylmethylamino)-1-hexyl hemi-succinate Mmt-hex-succ 1-Hydroxy-6-((4-methoxyphenyl)diphenylmethylamino)hexane (1.00 g; 2.57 mmol) is dissolved in anhydrous pyridine (10 ml). To this solution are added succinic anhydride (0.257 g; 2.57 mmol) and 4-dimethylaminopyridine (31.3 mg; 0.257 mmol). After stirring at 22 C for 3 hours, further succinic anhydride (25.7 mg; 0.257 mmol) and 4-dimethylaminopyridine (62.6 mg; 0.56 mmol) are added, and this solution is heated at 50 C for 6 hours.
After a further 16 hours at 22 C, the mixture is concen-trated, the residue is taken up in ethyl acetate, and the resulting solution is washed with ice-cold 5% strength aqueous citric acid. After the org. phase has been dried (Na2SO4)1 the solution is concentrated in a rotary evaporator. Purification of the residue by silica gel chromatography using 50% CH2C12/1% triethylamine in ethyl acetate and then using 5% methanol/1% triethylamine in dichloromethane affords the required compound as color-less oil.
MS (ES ) 978.0 (2M-H) , 488.3 (M-H) Rf 0.30 (CH2C12:ethyl acetate = 1:1).
Example 3 6-((4-Methoxyphenyl)diphenylmethylamino)-1-hexylsuccinyl-amido-Tentagel (Mmt-hex-succ-Tentagel) The amino form of TentagelR (Rapp polymers) (0.5 g;
0.11 mmol amino groups) is left to swell in 4-ethylmor-pholine (0.1 ml) and DMF (5 ml) for 10 minutes. A solu-tion of 6-((4-methoxyphenyl)diphenylmethylamino)-1-hexyl hemisuccinate (97.4 mg; 0.165 mmol), 4-ethylmorpholine (15.9 mg; 0.138 mmol; 17.4 ml) and TBTU (52.9 mg;
0.165 mmol) in DMF (3 ml) is then added, and the suspen-sion is shaken at 22 C for 16 hours. The derivatized Tentagel support is filtered off and washed successively with DMF (3 x 3 ml), CH2C12 (3 x 1 ml) and diethyl ether (3 x 1 ml) and dried. Unreacted amino groups are blocked by treatment with acetic anhydride/lutidine/1-methyl-imidazole in THF (1 ml) for 1 hour. The completed support is washed with CH2C12 (3 x 1 ml) and diethyl ether (3 x 1 ml) and dried in vacuo. Based on the monomethoxy-trityl group introduced, the loading is 168 mmolg-1.

Example 4 6-((4-Methoxyphenyl)diphenylmethylamino)-1-hexylsuccinyl-amidopropyl-controlled pore glass.
(Mmt-hex-succ-CPG) The preparation takes place in analogy to the description in Example 3 starting from aminopropyl-CPG (supplied by Fluka) (550 Angstrom; 1.0 g) and 6-((4-methoxyphenyl)-diphenylmethylamino)-1-hexyl hemisuccinate (48.7 mg;
0.082 mmol), 4-ethylmorpholine (7.6 ml) and TBTU
(26.4 mg; 0.082 mmol) in DMF (3 ml). The loading of the Mmt-hex-succCPG is 91 mmolg-1.
Example 5 N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N4-(4-tert-butylbenzoyl)-1-cytosylacetyl)glycine ( Mmt-Aeg ( ctBuBz ) -OH) 1.63 g (2.28 mmol) of N-((4-methoxyphenyl)diphenylmethyl-amino)ethyl-N-(N4-(4-tert-butylbenzoyl)-1-cytosylacetyl)-glycine methyl ester were dissolved in a mixture of 10 ml of dioxane and 1 ml of water and, while stirring at 0 C, 4.56 ml of 1 N NaOH were added dropwise. After 2 h, the pH was adjusted to 5 by dropwise addition of 1 N RHSOQ, and precipitated salts were filtered off and washed with a little dioxane. The combined filtrates were evaporated in vacuo, and the residue was coevaporated twice with methanol and dichloromethane. The crude product obtained in this way was purified by chromatography on silica gel using a gradient of 2-10% methanol and 1% triethylamine in dichloromethane. The fractions containing the product were combined and concentrated in vacuo. Excess triethyl-amine still present was removed by coevaporation with pyridine and then toluene. 0.831 g of product was obtained as an almost white foam.
Electrospray MS (negative ion) 700.7 (M-H) .
Rf 0.28 (CH2C12:MeOH/9:1), 0.63 (CH2C12:MeOH/7:3).
Example 6 N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-((1-thy-minyl)acetyl)glycine (Mmt-Aeg(t))-OH
The product from the above reaction was dissolved in a mixture of 10 ml of dioxane and 2 ml of water, the solution was cooled to 0 C, and 1 N sodium hydroxide solution was added dropwise until the pH reached 11.
After a reaction time of 2 h, the reaction was complete and the solution was adjusted to pH 5 by cautious addi-tion of 2 N RHSO4 solution. The solution was extracted three times with ethyl acetate, and the combined organic phases were dried over sodium sulfate and concentrated in vacuo. The crude product obtained in this way was puri-fied by chromatography on silica gel using a gradient of 5-10% methanol and 1% triethylamine in dichloromethane.
The fractions containing the product were combined and concentrated in vacuo. Excess triethylamine still present was removed by coevaporation with pyridine and then toluene. 1.065 g of product were obtained as a colorless foam.
Electrospray MS (negative ion) 1112.0 (2M-H) , 555.3 (M-H) Rf 0.28 (CH2C12:MeOH/8:2).
Example 7 N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N2-isobutanoyl-9-guanosylacetyl)glycine (Mmt-Aeg (g1B71) -OH

N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(NZ-iso-butanoyl-9-guanosylacetyl)glycine methyl ester (1.15 g;
1.72 mmol) is dissolved in dioxane (10 ml) and, at 0 C, 1 M aqueous sodium hydroxide solution (10.32 ml) is added dropwise in 5 portions over a period of 2.5 h. After a further reaction time of 2 h at room temperature, the solution is adjusted to pH 5 by dropwise addition of 2 M
aqueous potassium bisulfate solution. The precipitated salts are filtered off and washed with a little dioxane.
The combined filtrates are evaporated to dryness in vacuo, and the residue is coevaporated twice each with ethanol and 1/1 dichloromethane:methanol. Purification takes place by column chromatography on silica gel by elution with a gradient of 10-20% methanol in dichloro-methane (with 1% triethylamine). The product is obtained as a white foam.
Yield: 1.229 g ESMS (negative ion): 650.3 (M-H) Rf 0.25 (dichloromethane:methanol/8:2) Example 8 N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N6-(4-methoxybenzoyl)-9-adenosylacetyl)glycine (Mmt-Aeg ( aMeoBZ ) -OH) N-((4-Methoxyphenyl)diphenylmethylamino)ethyl-N-(N6-(4-methoxybenzoyl)-9-adenosylacetyl)glycine methyl ester (1.70 g; 2.38 mmol) is dissolved in dioxane (10 ml) and, at 0 C, 1 M aqueous sodium hydroxide solution (10.32 ml) is added dropwise in 5 portions over a period of 2.5 h. After a further reaction time of 2 h at room temperature, the solution is adjusted to pH 5 by dropwise addition of 2 M aqueous potassium bisulfate solution. The precipitated salts are filtered off and washed with a little dioxane. The combined filtrates are evaporated to dryness in vacuo, and the residue is coevaporated twice each with ethanol and 1/1 dichloromethane:methanol.
Purification takes place by column chromatography on silica gel by elution with a gradient of 10-20% methanol in dichloromethane (with 1% triethylamine). The product is obtained as a white foam.
Yield: 1.619 g ESMS (negative ion): 698.3 (M-H) Rf 0.10 (dichloromethane:methanol/8:2) Example 9 N-((4-Methoxyphenyl)diphenylmethyloxy)ethyl-N-((1-thy-minyl)acetyl)glycine (Mmt-Oeg(t)-OH) 0.5 g (1.28 mmol) of N-((4-methoxyphenyl)diphenylmethyl-oxy)ethylglycine was suspended in 10 ml of DMF, and 0.47 ml (1.92 mmol) of BSA was added dropwise. Then, 0.7 ml (5.1 mmol) of triethylamine and 0.26 g (1.28 mmol) of chlorocarboxymethylthymine were successively added.
The reaction mixture was stirred at room temperature for 4 h and then a further 65 mg (0.32 mmol) of chlorocar-boxymethylthymine were added, and the mixture was stirred for 16 h. The solvent was then stripped off in vacuo, and the crude product was purified on a silica gel column using a gradient of 5-15% methanol and 1% triethylamine in dichloromethane. The fractions containing the product were combined and concentrated in vacuo. The resulting brownish oil was dissolved in a little dichloromethane;
and the product was precipitated by adding diethyl ether.
The product was obtained as an almost white powder.
Yield: 0.219 g Electrospray MS (negative ion) 556.3 (M-H) .
Rf 0.54 (CH2C12:MeOH/8:2).

Example 10 4-Nitrophenyl 4-(4,41-dimethoxytrityloxy)butyrate Dmt-but-NPE

The sodium salt of 4-hydroxybutyric acid (1.26 g;
10 mmol) is dissolved in anhydrous pyridine (30 ml), and 4,4'-dimethoxytrityl chloride (3.39 g; 3.05 mmol) is added. After 16 hours, 4-nitrophenol (1.39 g; 10 mmol) and N,N'-dicyclohexylcarbodiimide (2.06 g; 10 mmol) are added, and the mixture is stirred at 22 C for a further 48 hours. The precipitated dicyclohexylurea is filtered off and washed with dichloromethane. The filtrate is concentrated and the resulting residue is coevaporated twice with toluene. The residue is purified on a silica gel column (10-50% ethyl acetate and 1% triethylamine in petroleum ether). The desired compound is obtained in the form of a pale yellowish-colored oil.
Yield: 2.694 g MS (FAB, MeOH/NBA/LiCl) 534.2 (M + Li)+, 527.2 M+.
Rf 0.34 (petroleum ether:ethyl acetate = 75:25) Example 11 H-Oprg(t) -OH

3.68 g of thyminylacetic acid are dissolved in 20 ml of dry DMF, and 6.65 g of TOTU and 2.77 ml of triethylamine are added. The mixture is stirred at room temperature for 30 min and then slowly added dropwise to a solution composed of 5.32 g of (3-hydroxypropyl)glycine, 20 ml of water, 20 ml of DMF and 5.54 ml of triethylamine. The mixture is stirred at room temperature for 1 h and then concentrated in a rotary evaporator in vacuo. The residue is taken up in water, adjusted to pH 1.5 with 1 N hydro-chloric acid and extracted with ethyl acetate. The aqueous phase is adjusted to pH 5 with saturated sodium bicarbonate solution and concentrated in a rotary evapor-ator. The residue is mixed with 250 ml of ethanol, and the sodium chloride precipitated thereby is filtered off with suction. The filtrate is concentrated and the crude product is purified by chromatography on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine followed by dichloromethane/
methanol/ethyl acetate 10:4:1 with the addition of 1%
triethylamine. The fractions containing the product are combined and concentrated in a rotary evaporator in vacuo.
Yield: 3.2 g Rf 0.15 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine) MS(ES+): 300.2 (M + H) Example 12 Dmt-Oprg(t)-OH
3.2 q of H-Oprg(t)-OH are dissolved in 40 ml of DMF, 5.93 ml of triethylamine are added and, at 0 C, a solu-tion of 7.25 g of Dmt-Cl in 40 ml of dichloromethane is added dropwise over the course of 20 min. The mixture is stirred at room temperature for 2 h, then the precipita-ted triethylamine hydrochloride is filtered off, and the filtrate is concentrated in a rotary evaporator in vacuo.
The residue is taken up in dichloromethane and extracted with water, and the organic phase is dried with sodium sulfate and concentrated in a rotary evaporator in vacuo.
The crude product is purified on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concentrated in a rotary evaporator in vacuo.
Yield: 3.46 g Rf 0.28 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine) MS (ES+) 602.4 (M + H)'.
Example 13 H-Obg(t) OH

2.76 g of thyminylacetic acid are dissolved in 15 ml of dry DMF, and 4.92 g of TOTU and 2.08 ml of triethylamine are added. The mixture is stirred at room temperature for 30 min and then slowly added dropwise to a solution composed of 4.41 g of (4-hydroxybutyl)glycine, 10 ml of water, 10 ml of DMF and 4.16 ml of triethylamine. The mixture is stirred at room temperature for 3 h and then concentrated in a rotary evaporator in vacuo. The residue is taken up in water, adjusted to pH 1.5 with 1 N hydro-chloric acid and extracted with ethyl acetate. The aqueous phase is adjusted to pH 5 with saturated sodium bicarbonate solution and concentrated in a rotary evaporator. The crude product is purified by chromato-graphy on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concen-trated in a rotary evaporator in vacuo.
Yield: 3.7 g Rf 0.11 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine) MS (ES+) 314.2 (M + H)+.
Example 14 Dmt-Obg(t)-OH
3.6 g of H-Obg(t)-OH are dissolved in 40 ml of DMF, 9.5 ml of triethylamine are added and, at 0 C, a solution of 15.4 g of Dmt-Cl in 40 ml of dichloromethane is added dropwise over the course of 15 min. The mixture is stirred at room temperature for 2 h, a further 40 ml of dichloromethane are added, then the precipitated triethylamine hydrochloride is filtered off, and the filtrate is concentrated in a rotary evaporator in vacuo.
The residue is taken up in dichloromethane and extracted with water, and the organic phase is dried with sodium sulfate and concentrated in a rotary evaporator in vacuo.
The crude product is purified on silica gel using dichloromethane/methanol/ethyl acetate 15:1:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concentrated in a rotary evaporator in vacuo.
Yield: 3.45 g Rf 0.29 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine) MS (ES+ + LiCl) 622.3 (M + Li)+.
Example 15 H-Opeg(t) OH

2.76 g of thyminylacetic acid are dissolved in 15 ml of dry DMF, and 4.92 g of TOTU and 2.08 ml of triethylamine are added. The mixture is stirred at room temperature for min and then slowly added dropwise to a solution composed of 4.83 g of (5-hydroxypentyl)glycine, 10 ml of water, 10 ml of DMF and 4.16 ml of triethylamine. The 25 mixture is stirred at room temperature for 3 h and then concentrated in a rotary evaporator in vacuo. The residue is taken up in water, adjusted to pH 1.5 with 1 N hydro-chloric acid and extracted with ethyl acetate. The aqueous phase is adjusted to pH 5 with saturated sodium 30 bicarbonate solution and concentrated in a rotary evaporator. The crude product is purified by chromato-graphy on silica gel using dichloromethane/methanol/ethyl acetate 10:2:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concen-trated in a rotary evaporator in vacuo.

21~~473-Yield: 3.34 g Rf 0.19 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine) MS (DC1) 328.2 (M + H)+.
Example 16 Dmt-Opeg(t)-OH
3.2 g of H-Opeg(t)-OH are dissolved in 40 ml of DMF, 6.77 ml of triethylamine are added and, at 0 C, a solu-tion of 9.94 g of Dmt-Cl in 40 ml of dichloromethane is added dropwise over the course of 15 min. The mixture is stirred at room temperature for 2 h, a further 40 ml of dichioromethane are added, then the precipitated triethylamine hydrochloride is filtered off, and the filtrate is concentrated in a rotary evaporator in vacuo.
The residue is taken up in dichloromethane and extracted with water, and the organic phase is dried with sodium sulfate and concentrated in a rotary evaporator in vacuo.
The crude product is purified on silica gel using dichloromethane/methanol/ethyl acetate 15:1:1 with the addition of 1% triethylamine. The fractions containing the product are combined and concentrated in a rotary evaporator in vacuo.
Yield: 3.6 g Rf 0.27 (dichloromethane/methanol/ethyl acetate 10:2:1 + 1% triethylamine) MS (ES + + LiCl) 636.4 (M + Li)+.
Example 17 5'-ATC GTC GTA TT-(but)-agtc-hex The DNA sequence is indicated in capital letters and the PNA sequence is indicated in small letters (example of the structural type XIIa in scheme 1). The PNAs are synthesized, for example, in an Ecosyn D-300 DNA synthe-sizer (from Eppendorf/Biotronik, Maintal) or an ABI 380B
DNA synthesizer (from Applied Biosystems, Weiterstadt).
The synthesis of the DNA part is carried out in principle by standard phosphoramidite chemistry and commercially obtainable synthesis cycles. For the synthesis of the PNA
part the methods of peptide synthesis are approximated to the DNA synthesis cycles as explained hereinafter.

H1N`
MO

CH, o~`q l o Y l U- P V N
1'Q`) Q
w r\r/~ LNI
H
o N
U-PY\ I (~n 0~
~ 0,-r, 0 B
U P V, 0(') n 0 o q~ a Y
u-v- ve N-~ M Q
CN, Y
0 N\
H 1\ ~ V-P-V\

y lk\~I_'0'"'`/1 Schsme 1 CHt Q ON
ONA/PNA hy6riC moIACUIo s ON
0 M Farmula XI11 N (XIII a; n=1) Formula X11 (XI I a, n=1) H=N\ ~
B l`

CH: 0 o~`p B
Y
U -P- V N
ii ~ CH= 0 w O~N\ B
Y H I
8 `
U P - V
r N0~ 0 0 X CN~
N BI
H~ ~oV
U -P -V B\Y/
W
N

CH U-P-V\ 8 }r OY`~
ON\ B
Y
H I\
N

CH= jy O1^1 N g `iF

PNA/DN- hybrid Yolooulet CH2 OH
Sthem= 2 0 N Formula XI
H

Formula X (Xo, V-0; Xb, V-NH) Dmt -V 80 I
R5-' p-, Rs Formulo V I I I

VIII a NC-CH CH -0- -N(i-C H )H 0 VIII b CH -N(i-C H )H 0 VIII c C H -N(i-C H )H 0 VIII d C H-C(O)-S(CH )-S -N-pyrrolidin-1 I H 0 VIII e NC-CH CH -0- -N(i-CH1 OCH 0 VIII f NC-CH CH -0- -N(i-C H )H NH
Mm t - V B ' ( n I I
N ~O
CHZ
I

Formulo IX (IXa, V=NH; IXb, V=O) with n 1-8, preferably 1-5, y , \P B

0-Dmt NC

Formulo XIV
y N,,, - -~ p/OL~j~Of-,, Omi f NC
Formulo XV
~--r N Wmt I \P/0 N/
H

f NC

Formulo XVI
3 mol of the CPG support loaded with Mmt-hex-succ (loading 91 mol/g) from Example 4 are treated succes-sively with the following reagents:

Synthesis of the PNA part (agtc-hex):
1. dichloromethane 2. 3% trichloroacetic acid in dichioromethane 3. acetonitrile abs.
4. 3.5 M solution of 4-ethylmorpholine in acetonitrile (neutralization) 5. 0.4 M solution of (Mmt-Aeg(ctB'BZ)-OH) from Example 5 in acetonitrile:DMF = 9:1/0.9 M solution of ByBOP in acetonitrile/3.5 M solution of 4-ethylmorpholine in acetonitrile (coupling time of 10 minutes).
6. step 5 is repeated four times.
7. acetonitrile Steps 1 to 7, called a PNA reaction cycle hereinafter, are repeated 3 times to assemble the PNA part, using in step 5 in each case the monomer building block, necessary according to the sequence, from Examples 5 to S.

Conjugation of the linker (agtc-hex ---> (but)-agtc-hex):
8. repeat steps 1 to 4 from above 9. 4-nitrophenyl 4-(4,4'-dimethoxytrityloxy)butyrate (105 mg) from Example 10 and hydroxybenzotriazole (27 mg) in 2 ml of NEM in DMF for 15 hours 10. wash with DMF
11. wash with acetonitrile 12. dichloromethane Synthesis of the DNA part ((but)-agtc-hex) --> 5'-ATC GTC GTA TT-(but)-agtc-hex):
13. acetonitrile abs.
14. 3% trichloroacetic acid in dichioromethane 15. acetonitrile abs.
16. 10 mol of R-cyanoethyl 5'-O-dimethoxytritylthymi-dine 3'-diisopropylphosphoramidite and 50 mol of tetrazole in 0.3 ml of acetonitrile abs.
17. acetonitrile 18. 20% acetic anhydride in THF with 40% lutidine and 10% dimethylaminopyridine 19. acetonitrile 20. iodine (1.3 g in THF/water/pyridine; 70:20:5 = v:v:v) Steps 13 to 20, called a DNA reaction cycle hereinafter, are repeated 10 times to assemble the nucleotide part, using in step 16 in each case the P-cyanoethyl 5'-O-di-methoxytrityl(nucleotide base) 3'-diisopropylphosphor-amidite corresponding to the sequence.

After the synthesis is complete, the dimethoxytrityl group is eliminated as described in steps 1 to 3. The oligomer is cleaved off the support and, at the same time, the (3-cyanoethyl groups are eliminated by treatment with ammonia for 1.5 hours. To eliminate the exocyclic amino protective groups, the ammoniacal solution is kept at 55 C for 5 hours. 180 OD260 of the resulting crude product (325 OD260) of 5' -ATC GTC GTA TT- (but) -agtc-hex are purified by polyacrylamide gel electrophoresis.
Desalting on a BiogelR column (from Biorad) results in 50 OD260 of high-purity oligomer from this.

Example 18 5'-ATC GTC GTA TT-(Oeg(t))-agtc-hex (Example of structural type Xa in scheme 2; see Example 9 for explanation of Oeg(t)) The synthesis takes place in analogy to the description in Example 17 but in step 9 coupling the linker building block Mmt-Oeg(t)-OH from Example 9, in place of the p-nitrophenyl Dmt-butyrate, under the conditions described in step S. 135 OD260 of the resulting crude product (235 OD260) of 5'-ATC GTC GTA TT-(Oeg(t)-agtc-hex are purified by polyacrylamide gel electrophoresis.
Desalting on a BiogelR column (from Biorad) results in 20 OD260 of high-purity oligomer from this.
Example 19 N-ggg g(5'NH-C)T CSCSAS TGG GGSGS T (sequence complemen-tary to HSV-1) (Example of structural type XI in scheme 2; s means a phosphorothioate bridge; (5'NH-C) means a 5'-aminocytidy-late residue; N equals amino terminus) The synthesis takes place starting from a CPG support on which 5'-Dmt-thymidine is bound via its 3' end. The synthesis of the DNA part is first carried out as described in Example 17 (steps 13 to 20), carrying out the oxidation in step 20 in the case of the phosphoro-thioate bridges (S) using tetraethylthiuram disulfide (TETD; User Bulletin No. 65 of Applied Biosystems Inc.).
A Dmt-protected 5'-amino-5'-deoxycytidylate 3'-phosphor-amidite building block of the formula VIIIf is used as linker building block. The PNA building blocks are then condensed on in analogy to steps 1 to 7 in Example 17.
After the synthesis is complete, the oligomer is cleaved off the support and, at the same time, the R-cyanoethyl groups are eliminated by treatment with ammonia for 1.5 hours. To eliminate the exocyclic amino protective groups, the ammoniacal solution is kept at 55 C for 5 hours. Only then is the monomethoxytrityl group elimi-nated by treatment with 80% strength acetic acid at 22 C
for 2 hours. The product is purified by polyacrylamide gel electrophoresis and desalted on a BiogelR column (from Biorad).

Example 20 5' -GmeGMeG GCT CCA (Oeg (t) ) gg ggg t-hex (Example of structural type Xa in scheme 2; 2õte means a methylphosphonate bridge; see Example 9 for explanation of Oeg(t)) The synthesis takes place in analogy to the description in Example 18 but using the appropriate methylphosphonate building blocks of the formula VIIib in the DNA reaction cycle to incorporate the methylphosphonate bridges Me.
Example 21 5'-C$ SAS SC GTs ST GAG (but)Ggg cat-hex (c-myc antisense) (Example of structural type XIIa in scheme 1; S s means a phosphorodithioate bridge). ~

The synthesis takes place in analogy to the description in Example 17 but the building block VIIid is used to incorporate the dithioate bridges, and the oxidation at these sites (step 20) is carried out with TETD.

Example 22 N-cga g(5'NH-A)A CAT CA (Oeg(t))ggt cg-hex (c-fos antisense) (5'NH-A means 5'-amino-5'-deoxyadenylate; see Example 9 for explanation of Oeg(t)) The synthesis takes place in analogy to the description in Example 18 with, after completion of the DNA syn-thesis, in analogy to Example 13 condensation on of a 5'-aminonucleotide which permits conjugation of the second PNA part. Thus, firstly six PNA synthesis cycles are carried out and then the linker building block from Example 9 is coupled on. Then seven DNA synthesis cycles are carried out, using the building block of the formula VIIIf in the last cycle. After a further four PNA syn-thesis cycles have been carried out, the elimination from the support and further working up are carried out as described in Example 19.

Example 23 F-cga g(5'NH-A)A CAT CAT GGT SCSG-O-CH2CH(OH)CH2-O-C16H33 (5'NH-A means 5'-amino-5'-deoxyadenylate; F a fluorescein residue on the amino terminus of the PNA and S a phosphorothioate bridge) The synthesis takes place in analogy to the description in Example 19 but starting from a CPG support onto which the glycerol hexadecyl ether is bound. After 12 DNA
synthesis cycles have been carried out, the linker building block VIIIf is condensed on. After four PNA
synthesis cycles have been carried out and the terminal Mmt group has been eliminated, it is possible to react the free amino group quantitatively with a 30-fold excess of fluorescein isothiocyanate (FITC).

Example 24 3'-CCC TCT T-5'-(PEG)(PEG)-(Oeg(t))tg tgg g-hex (PEG means a tetraethylene glycol phosphate residue) The synthesis in respect of the PNA part takes place in analogy to the description in Example 17. After six PNA
units have been condensed on, the (Mmt-Oeg(t)-OH) from Example 9 is coupled on. Then as linker initially the tetraethylene glycol derivative of the formula XV is condensed on twice as described in the DNA synthesis cycle before the synthesis of the DNA part with reversed orientation (from 5' to 3') is carried out. For this purpose, in place of the nucleoside 3'-phosphoramidites in each case the corresponding nucleoside 5'-phosphor-amidites of the formula XIV, which are commercially available, are used in step 16 in the DNA synthesis cycles. Further deprotection and working up take place as described in Example 17.

Example 25 N-ccc tct t-(C6-link)(PEG)-3'-AAG AGG G-5' (PEG means a tetraethylene glycol phosphate residue;
C6-link is a 6-aminohexanol phosphate residue) The synthesis takes place in analogy to the description in Example 17 (DNA synthesis cycle) but starting from a CPG support to which 3'-O-Dmt-deoxyguanosine is bound via a 5'-O-succinate group. After six DNA units have been condensed on using the building blocks of the formula XIV, initially the tetraethylene glycol derivative of the formula XV is condensed on once as linker before coupling the phosphoramidite of the formula XVI to introduce C6-link. The PNA part is then synthesized on as in Example 17 (PNA synthesis cycle). Further deprotection and working up take place as described in Example 19.
Example 26 5'-TTT TTT TTT (but) ttt ttt-hex The synthesis takes place in analogy to the description in Example 17. Before the product is cleaved off the support and deprotected, half the support-bound DNA/PNA
hybrid is taken for fluorescence labeling (Example 27).
The other half is deprotected and worked up as described in Example 17.

Example 27 (FAM is fluorescein residue) 5'-FAM-TTT TTT TTT (but) ttt ttt-hex The support-bound DNA/PNA hybrid from Example 26 is fluorescence labeled by carrying out steps 13 to 20 as described in Example 17 using the fluorescein phosphor-amidite from Applied Biosystems in step 16.

Example 28 5'-GGG GGG GGG (but) ttt ttt-hex The synthesis takes place in analogy to the description in Example 17. Before the product is cleaved off the support and deprotected, half the support-bound DNA/PNA
hybrid is taken for fluorescence labeling (Example 29).
The other half is deprotected and worked up as described in Example 17. The title compound binds as triplex-forming oligonucleotide with high affinity to a DNA
double strand which contains the homopurine motif 5'-AAA AAA GGG GGG GGG-3'.
Example 29 (FAM is fluorescein residue) 5'-FAM-GGG GGG GGG (but) ttt ttt-hex The support-bound DNA/PNA hybrid from Example 28 is fluorescence labeled by carrying out steps 13 to 20 as described in Example 17 using the fluoresceine phosphor-amidite from Applied Biosystems in step 16.

Example 30 Biotin-CpheGPheA GAA cat ca t(5' NH-G) G(Ome) U(Ome) C(Ome) -G(Ome)-VitE (c-fos antisense) (N(Ome) means a nucleotide unit N with a 2'-O-methoxy group; Phe means a phenylphosphonate bridge; 5'NH-G means 5'-amino-5'-deoxyguanylate).

The synthesis takes place in analogy to the description in Example 17 starting from CPG which is loaded with vitamin E(MacRellar et al. (1992) Nucleic Acids Res, 20(13), 3411-17) and coupling the building block of the formula VIIIe four times after the DNA synthesis cycle.
After the 5'-aminonucleotide building block of the formula VIIIf has been coupled on, six PNA units are condensed on after the PNA synthesis cycle. After neutra-lization, the phosphoramidite is coupled to the amino group by a known method, and the DNA synthesis cycle is repeated appropriately to assemble the DNA part, using in the case of the phenylphosphonate bridges the building blocks of the formula VIIIc in step 16. Lastly the end group is coupled on using the biotin phosphoramidite from Glen Research. After the synthesis is complete, the oligomer is deprotected as described in Example 19, eliminating the dimethoxytrityl group at the end by treatment with 80% strength acetic acid at 22 C for 2 hours.
Example 31 A CAT CA (Oeg(t)) ggt cg-hex (c-fos antisense) (See Example 9 for explanation of Oeg(t)) The synthesis takes place in analogy to the description in Example 18. In this case, firstly five PNA synthesis cycles are carried out and then the linker building block Oeg(t) from Example 9 is coupled on. Then six DNA syn-thesis cycles are carried out. Subsequently, the elimi-nation from the support and the further working up are carried out as described in Example 18.

Example 32 A TAA TG (Oeg(t)) tct cg-hex (control oligomer for c-fos) The synthesis takes place in analogy to the description in Example 18. In this case, firstly five PNA synthesis cycles are carried out and then the linker building block Oeg(t) from Example 9 is coupled on. Then six DNA syn-thesis cycles are carried out. Subsequently, the elimi-nation from the support and the further working up are carried out as described in Example 18.

Example 33 a cat cat ggt cg-hex (c-fos antisense) This pure PNA oligomer was prepared as reference compound in analogy to Example 18 but with the exception that twelve PNA cycles were carried out. Deprotection of the exocyclic amino protective groups is carried out in ammoniacal solution (5 hours at 55 C). Only then is the monomethoxytrityl group eliminated by treatment with 80%
strength acetic acid at 22 C for 2 hours.

Example 34 A (5-hexy-C)A(5-hexy-U) (5-hexy-C)A (Oeg(t)) ggt cg-hex (c-fos antisense) (See Example 9 for explanation of Oeg(t); 5-hexy-C means 5-hexynylcytidine, 5-hexy-U means 5-hexynyluridine) The synthesis takes place in analogy to the description in Example 31 but using in place of the normal pyrimidine phosphoramidites the corresponding 5-hexynylpyrimidine nucleoside phosphoramidites in the condensation reaction.
Example 35 (FAM is fluorescein residue) 5'-FAM-TT (but) ttt ttt-hex The synthesis of this PNA/DNA oligomer takes place in analogy to the description in Example 27 although only two thymidylate units are condensed on.

Example 36 taa tac gac tca cta (5'HN-T) (5'HN-T means 5'-amino-51-deoxythymidine) This PNA/DNA oligomer which is composed of 15 PNA units and one nucleoside unit was synthesized as primer for the DNA polymerase reaction. This entails starting from a solid phase support (aminoalkyl-CPG) to which the 5'-monomethoxytritylamino-5'-deoxythymidine is bound via its 3'-hydroxyl group as succinate. After elimination of the monomethoxytrityl group with 3% TCA in dichloro-methane, 15 PNA cycles are carried out as described in Example 17. Deprotection of the exocyclic amino protec-tive groups is carried out in ammoniacal solution (5 hours at 55 C). Only then is the monomethoxytrityl group eliminated by treatment with 80% strength acetic acid at 22 C for 2 hours. A PNA/DNA oligomer with a free 3'-hydroxyl group, which is used as primer for a DNA
polymerase (Klenow) is obtained.

Example 37 ps-rA(2'5')rA(2'5')rA(2'5')rA-spacer-(Oeg(t)tc ctc ctg cgg-hex (ps means a 5'-thiophosphate; spacer means a triethylene glycol phosphate; rA is a riboadenylate; (2'5') means that the internucleotide linkage is from 2' to 5' in the ribose) The synthesis of this compound takes place in analogy to the description in Example 18 by initially condensing on 14 PNA units. After the linker building block Mmt-Oeg(t)-OH from Example 9 has been introduced under the conditions described in step 5, the Mmt group is eliminated with 3% TCA, and the spacer is introduced with the aid of the commercially available Dmt-O-(CH2CH2O)3-O-P(-OCH2CH2CN)N(i-C3H7)3 spacer phosphoramidite (from Eurogentech; Brussels). The (2'5')-linked tetradenylate is synthesized on as described in Example 17 using the commercially available N6-benzoyl-5'-O-Dmt-3'-O-tert-butyldimethylsilyladenosine 2'-O-cyanoethyl diisopropyl-aminophosphoramidite (from Milligen, Bedford, USA), extending the condensation time to 2 x 5 min. The stronger activator 5-ethylthiotetrazole is used in place of tetrazole in the coupling reaction. After elimination of the last Dmt group, the oligomer is phosphitylated on the 5'-OH group with bis(R-cyanoethyloxy)diisopropyl-aminophosphine. Oxidation with TETD and deprotection with ammonia and desilylation with fluoride result in the title compound, which stimulates RNase L.

Example 38 ps-Co(2'S')Co(2'5')Co(2'5')Co-spacer-(Oeg(t))tc ctc ctg cgg-hex (ps means a 5'-thiophosphate; spacer means a triethylene glycol phosphate; Co is cordycepin (3'deoxyadenosine);
(2'5') means that the internucleotide linkage is from 2' to 5') The synthesis is carried out in analogy to Example 37 but in place of the N6-benzoyl-5'-O-Dmt-3'-O-tert-butyl-dimethylsilyladenosine 2'-O-cyanoethyl diisopropylamino-phosphoramidite, the corresponding N6-benzoyl-5'-O-Dmt-cordycepin 2'-O-cyanoethyl diisopropylaminophosphorami-dite (from Chemogen, Konstanz) is used, and the fluoride treatment is omitted.
Example 39 5'-GG GGG GGG (Oeg(t)) ttt ttt ttt-hex The synthesis takes place in analogy to the description in Example 18, following nine PNA couplings by condensa-tion on of the linker building block Mmt-Oeg(t)-OH from Example 9 under the conditions described in step 5, which permits subsequent condensation of eight guanylate residues. The resulting PNA/DNA oligomer binds with high affinity in the antiparallel orientation as triplex-forming oligonucleotide to double-stranded DNA which has the sequence 5'.. GGGGGGGG..3'.

Example 40 Characterization of the PNA/DNA hybrids The characterization takes place with the aid of HPLC, polyacrylamide gel electrophoresis (PAGE) and negative ion electrospray mass spectrometry (ES-MS-). The products are purified as described above and thereafter show in the PAGE (20% acrylamide, 2% bisacrylamide and 7 M urea) a single band. The HPLC takes place on RP-18 reversed phase columns from Merck (eluent A: water with 0.1% TFA, B: water/acetonitrile = 1:4; linear gradient) or on a PA-100 column from Dionex (eluent A: 20 mM NaOH and 20 mM
NaCl; B: 20 mM NaOH and 1.5 M NaCl; linear gradient). For the ES-MS , the PNA/DNA hybrids are converted by ammonium acetate precipitation or other metathesis into the ammonium salts. Sample introduction takes place from a solution in acetonitrile/water (1:1) containing 5 OD260/ml oligomer. The accuracy of the method is about 1.5 Dalton.

Example 41 Determination of cellular uptake and stability after radioactive labeling Radioactive labeling:
A generally applicable labeling with 35S comprises carrying out at least one oxidation in the DNA synthesis cycle (step 20 in Example 17) for the synthesis of the DNA part using elemental sulfur-35. PNA/DNA hybrids which have a free 5'-hydroxyl group can be labeled with 32P or 35S with the aid of polynucleotide kinase by methods known per se. PNA/DNA hybrids which carry a free 3'-hydroxyl group can be labeled in a known manner with 3'-terminal transferase. As an example, the 5'-labeling of the DNA part is described here: the PNA/DNA hybrid with a free 5'-hydroxyl group (500 pmol) from Example 17, 18 or 26 is dissolved in 425 1 of water, and this solution is heated to 90 C and rapidly cooled. Then 50 l of 10 x kinase buffer and 50 l of 32P-gamma-ATP
(6,000 Ci/mmol) or 35S-gamma-ATP are added, and the mixture is incubated at 37 C for 1 hour. The reaction is stopped by adding 0.5 M EDTA solution. Desalting takes place with the aid of an NAPR column from Pharmacia.
Determination of cellular uptake:
Vero cells are incubated in DMEM, 5% FCS, in 96-well microtiter plates at 37 C for 24 hours. After removal of the medium, the cells are washed twice with serum-free DMEM. The radioactively labeled oligomer (106 cpm) is diluted with unlabeled oligomer to a concentration of 10 M in serum, and the cells are incubated at 37 C
therewith. 150 l portions are removed after 1, 7 and 24 hours (called "supernatant 1"). The cells in the wells of the microtiter plates are washed 7 times with 300 l of fresh medium, and the combined washing media (called "supernatant 2") are measured in a scintillation counter.
30- Then 100 l of trypsin solution are added, 30 seconds are allowed to elapse, and the supernatant is aspirated off.
The cells are detached from the plate by incubating at 37 C for 3 min. The detached cells are transferred into 1.5 ml Eppendorf tubes and centrifuged at 2,000 rpm for 6 minutes ("supernatant 3"). Supernatants 1 (5 l), 2 and 5 (0.5 ml) are each measured separately in a scintilla-tion counter. From this is calculated the uptake of oligomer in pmol per 100,000 cells, with supernatant 3 representing the cell-bound oligomer fraction and the total of supernatants 1 and 2 representing the non-cell-bound oligomer fraction.

Results:
Incubation time Cellular uptake in pmol in hours of oligomer/105 cells PNA/DNA hybrid DNA
1 0.25 0.36 7 0.54 0.57 24 0.75 0.78 Investigation of the stability of the oligomer in medium containing cells:
Supernatant 1 (10 l) is mixed with 5 l of 80% formamide (with Xylenecyanol and bromphenolblue), heated to 95 C
(5 minutes) and loaded onto a polyacrylamide gel (20%
acrylamide, 7 M urea) . After development of the gel in the electric field, the bands on the gel are assigned by autoradiography to the "stable oligomer", and the missing bands to the "degraded oligomer".

The PNA/DNA oligomer from Example 26 is 69% stable after an incubation time of 24 hours; the DNA oligomer is 3%
stable.

The PNA/DNA oligomer from Example 31 has a half-life of 32 h under these conditions, whereas the corresponding DNA oligonucleotide has a half-life of about 2 h.

Example 42 Determination of cellular uptake by fluorescence labeling:

COS cells are allowed to grow to confluence in Dulbecco's MEM supplemented with 10% FCS in 5 cm Petri dishes. The cells are washed twice with serum-free DMEM. A sterile needle is used to scratch an area of about 1 cm2 in the 214447a middle of the Petri dish. The PNA/DNA oligomer solution (0.1 mM) to be investigated is applied to this area.
Incubation is carried out at 37 C under a CO2 atmosphere.
The cells are investigated by fluorescence microscopy after 2, 4 and 16 hours. For this, the cells are washed four times with serum-free DMEM, covered with a glass slide and assessed under a fluorescence microscope or by phase contrast. A fluorescence-labeled PNA (without DNA
part) F-(but)-tttt ttt-hex was investigated as comparison for the PNA/DNA hybrid molecules. After the cells had been incubated with this PNA for two hours, > 90% of the cells show signs of pronounced morphological changes and cell death. Most of the cells exhibit pronounced vacuo-lization. The plasma membrane, the cytosol and the nucleus show no uptake of PNA. After incubation with the pure PNA for a further two hours, all the cells have died. The situation is different with the DNA/PNA oligo-mers according to the invention. After incubation of the cells with the DNA/PNA oligomers for only two hours the cells show punctiform intracellular distribution of the PNA/DNA oligomers. The cells suffer no cell death even after prolonged incubation.

Example 43 Determination of the melting temperatures:

The melting temperatures are determined using an HP 8452A
diode array spectrophotometer, an HP 89090A Peltier element and the HP temperature control software Rev.B5.1 (from Hewlett Packard). Measurements are carried out in 0.5 C/min steps in 10 mM HEPES and 140 mM NaCl (pH 7.5) as buffer. The oligomer concentration is 0.5 to 1 OD260 per ml.

214447~
Result for the product from Example 17 or 18 (TM with DNA) 5'-ATC GTC GTA T(Oeg(t))a gtc-hex TM = 51.5 C
3'-TAG CAG CAT A A T CAG-5' antiparallel 5'-ATC GTC GTA T(Oeg(t))a gtc-hex TM < 20 C
5'-TAG CAG CAT A A T CAG-3' parallel 5'-ATC GTC GTA TT(but)a gtc-hex TM = 51.0 C
3'-TAG CAG CAT AA T CAG-5' antiparallel 5'-ATC GTC GTA TTA GTC-3' TM = 50.5 C
3'-TAG CAG CAT AAT CAG-5' DNA=DNA antiparallel 5'-ATC GTC GTA TT(but)a gtc-hex TM < 20 C
5'-TAG CAG CAT AA T CAG-3' parallel Sequence T. with DNA TM with RNA
(T = U) 5'-ACA TCA TGG TCG-3' DNA ap 50.7 C 48.6 C
3'-TGT AGT ACC AGC-5' 5'-ACA TCA tgg tcg-3' (PNA/DNA) ap 54.5 C 54.7 C
3'-TGT AGT ACC AGC-5' 5'-ACA TCA tgg tcg-3' (PNA/DNA) p 20 C < 20 C
3'-TGT AGT ACC AGC-3' 5'-aca tca tgg tcg-3' PNA ap 58.8 C 66.6 C
3'-TGT AGT ACC AGC-5' 5'-aca tca tgg tcg-3' PNA p 46.3 C 44.8 C
5'-TGT AGT ACC AGC-3' 5'-ACA TCA TGG TCG-3' S-DNA ap 46.7 C 43.8 C
3'-TGT AGT ACC AGC-5' TGG TCG means a DNA part in which all internucleotide linkages are in phosphorothioate form. See page 5 for definition of p and ap.
Example 44 Tests for antiviral activity:
The antiviral activity of the test substances on various human-pathogenic Herpesviruses is investigated in a cell culture test system. For the experiment, monkey kidney cells (Vero, 2 x 105/ml) are inoculated in serum-contain-ing Dulbecco's MEM (5% fetal calf serum FCS) in 96-well microtiter plates and incubated at 37 C and 5% C02 for 24 h. The serum-containing medium is then aspirated off and the cells are rinsed twice with serum-free Dulbecco's MEM (-FCS). The test substances are prediluted in H20 to a concentration of 600 M and stored at -18 C. Further dilution steps in Dulbecco's minimal essential medium (MEM) are carried out for the test. 100 l portions of the individual test substance dilutions are added to-gether with 100 l of serum-free Dulbecco's MEM (-FCS) to the rinsed cells. After incubation at 37 C and 5% C02 for 3 h, the cells are infected with Herpes simplex virus type 1 (ATCC VR733, HSV-1 F-strain) or with Herpes simplex virus type 2 (ATCC VR734, HSV-2 G-strain) in concentrations at which the cell lawn is completely destroyed within 3 days. The infection concentration for HSV-1 is 500 plaque-forming units (PFU) per well, and for HSV-2 it is 350 PFU/well. The test mixtures then contain test substance in concentrations of 80 M to 0.04 M in MEM supplemented with 100 U/ml penicillin G and 100 mg/1 streptomycin. All the experiments are carried out as duplicate determination with the exception of the con-trols which are carried out eight times per plate. The test mixtures are incubated at 37 C and 5% C02 for 17 h.
The cytotoxicity of the test substances is determined after a total incubation time of 20 h by microscopic inspection of the cell cultures. The maximum tolerated dose (MTD) is defined as the highest concentration of product which, under the stated test conditions, does not yet cause microscopically detectable cell damage.
Subsequently FCS is added to a final concentration of 4%, and incubation is continued at 37 C and 5% C02 for 55 h.
The untreated infection controls then show a complete cytopathic effect (CPE). After microscopic inspection of the cell cultures they are then stained with neutral red in accordance with the vital staining method of Finter (1966). The antiviral activity of a test substance is defined as the minimum inhibitory concentration (MIC) which is needed to protect 30-60% of the cells from the cytopathogenic effect caused by the virus. The activity of the PNA/DNA chimeras is in each case better than that of the corresponding DNA oligomers or PNA oligomers.
Example 45 Determination of the in vivo activity: inhibition of c-Fos protein expression in the rat:

The determination takes place as described (SandkUhler et al. (1991) in: Proceedings of the VIth World Congress on Pain, Charlton and Woolf, Editors; Elsevier, Amsterdam;
pages 313-318) by superfusion of the spinal cord. After laminectomy of a barbiturate-anesthetized Sprague-Dawley rat, a two-chamber container is formed from silicone to receive the antisense oligomer. One chamber is filled with the antisense PNA/DNA derivative, while the other chamber is filled with the control oligomer (concentra-tion of each 75 M). The superfusate is exchanged in each case after one hour. After superfusion for 6 hours, c-fos expression is stimulated by heat treatment (52 C) of the rear legs. Inhibition of c-fos expression can be demon-strated immunohistochemically on appropriate tissue section samples. The c-fos antisense oligonucleotide from Example 31 brings about greater inhibition of c-fos expression than does the corresponding DNA oligonucleo-tide and the corresponding PNA oligomer from Example 33.
Example 46 RNase H assay To determine the RNase H activity, 1.3 OD of the PNA/DNA
oligomer to be investigated are heated with 0.5 OD of the complementary RNA sequence (target sequence) dissolved in 50 l of autoclaved water, treated with DEPC (diethyl pyrocarbonate), at 80 C for 5 minutes and subsequently cooled to 37 C within 15 minutes. This results in initial denaturation of both oligomers which, after cooling, form a nucleic acid double strand in sequence-specific manner.
For the assay, this RNA-PNA/DNA duplex is incubated with 10 l of RNase H 10 x buffer, 1 l of dithiothreitol (DTT) and 2 l (corresponding to 10 u) of RNase H
supplied by USB. The incubation mixture is made up with autoclaved, DEPC-treated water to the required total volume of 100 l. The samples are incubated as 37 C. For the kinetic investigation, 20 l portions of the solution were removed after 0, 2 min, 10 min and 1 h, heated at 95 C for 5 minutes and frozen at -70 C until analyzed.
The investigation of the RNase H cleavage of RNA takes place by gel electrophoresis. It emerged that PNA/DNA
hybrids which contain deoxyribonucleotide building blocks activate RNase H, with cleavage of the complementary RNA
strand whereas the PNA/DNA oligomer emerges undamaged from the reaction. The cleavage reaction with the PNA/DNA
oligomer takes place somewhat more slowly than with a corresponding oligodeoxyribonucleotide of equal length and sequence.

Example 47 Preparation of an HeLa cell extract with RNase L activity An HeLa cell extract was prepared in order to stimulate the activity of cellular endoribonuclease L by the 2',5'-tetraadenylate-PNA/DNA conjugates. For this pur-pose, 35 bottles were each charged with 20 ml of medium containing Dulbecco's MEM (mimimal essential medium) and 10% FCS (fetal calf serum) . The cells can be harvested after trypsin treatment. 4 ml of cell harvest are obtained after centrifugation at 1,000 rpm. This is initially made up with 4 ml of water and, after 3 minutes, 4 ml of buffer A (5.48 g of HEPES; 15.5 g of KC1; 2.488 g of Mg acetate; 1,232 l of 2-mercaptoethanol ad 1 1 with water) are added in order to lyze the cells.
The solution is then centrifuged at 30,000 rpm (about 100,000 g) in an ultracentrifuge at 0 C for 30 minutes.
The supernatant from 8 ml of cell extract is removed and stored at -20 C for the following investigations.
Example 48 Investigation of activiation of RNase L

For investigation of this extract for endonuclease L, initially 0.3 OD of the RNA target sequence is heated with the particular PNA/DNA oligomers at 80 C for 5 minutes and subsequently cooled to 37 C for the hybridization. The duplex is mixed with 20 l of the extract, 1.2 l of glycerol and RNase L buffer and incubated at 37 C. The total volume is then 70 l. For the kinetic investigations, samples are removed by pipette at the times of 0, 20 and 60 minutes and heated at 95 C for 5 minutes to denature the enzymes. The samples are lyophilized in a Speedvac and analyzed by gel electrophoresis. The PNA-2',5'-tetraadenylate conjugates and tetracordycepin analogs activate cellular RNase L, whereas corresponding compounds without the tetra-adenylate part do not stimulate RNase L.

Example 49 DNA polymerase reaction The following 81-mer oligodeoxynucleotide is used as template for the DNA polymerase reaction:

5'-GCC CCA GGG AGA AGG CAA CTG GAC CGA AGG CGC TTG TGG AGA AGG AGT
TCA TAG CTG GGC TCC CTA TAG TGA GTC GTA TTA-3' The sequence of the PNA/DNA primer is:
H-taa tac gac tca cta (5NH-T)-OH 3'.

A corresponding oligodeoxynucleotide of the sequence 5'-TAA TAC GAC TCA CTA TAG-3' is used as control primer.
The primer (0.15 nmol) and the template (0.15 nmol) in 5 l of 10 x PCR buffer (500 m RC1, 100 mM tris-HC1, pH 9, 1% Triton X-100, 15 mM MgC12) are diluted with 35 l of water and hybridized by heating to 95 C and cooling. Then 10 l of 2 mM dNTP mixture (nucleoside 5'-triphosphates) and 3 l of DNA polymerase (Rlenow fragment) are added, and the mixture is incubated at 22 C
and 37 C for 0.5 hour each. The reaction solution is then analyzed on a 10% polyacrylamide gel (with 1% bis).
pBR322/HaeIII digestion is loaded as marker. The reaction with the control primer shows a double-stranded DNA
fragment with the expected size relative to the marker, whereas the product from the PNA/DNA primer migrates somewhat more quickly. In both cases the double strand migrates considerably faster than the template single strand in the gel electrophoresis.

Claims (15)

1. A polyamide-oligonucleotide derivative selected from the group consisting of formulae Ia, Ib and mixtures thereof wherein x is 1;
q = r = 1 and s = t = zero or r = s = 1 and q = t = zero or q = r = s = 1 and t = zero;

R2 is hydrogen, hydroxyl, C1-C18-alkoxy, halogen, azido or amino;
B is, independently of one another, a base custo-mary in nucleotide chemistry, and the "curved bracket" indicates that R2 and the adjacent substituent can be in the 2' posi-tion and 3' position or else conversely in the 3' position and 2' position;
Nu is a radical of the formulae IIa or IIb in which R2 and B are as defined above;
U is hydroxyl, mercapto, C1-C18-alkyl, C1-C18-alkoxy, C6-C20-aryl, C6-C14-aryl-C1-C8-alkyl, NHR3 or NR3R4, and R3 is C1-C18-alkyl or C1-C4-alkoxy-C1-C4-alkyl, and R4 is C1-C18-alkyl or R3 and R4 is, together with the nitrogen atom carry-ing them, a 5-6-membered heterocyclic ring which can additionally contain another hetero-atom from the series consisting of O, S, N;
V is oxy, thio or imino;
W is oxo or thioxo;
Y is oxy, thio, methylene or imino;
m is zero to 20;
o is zero to 20;
D is a radical of the formula III
in which B is as defined above;
D' is a radical of the formula IV

in which B is as defined above;
n is zero to 20;
p is zero to 20;
Li1, Li2, Li3 and Li4 are each, independently of one another, a structure of the formula V
[(v')-(G)-(G')].epsilon. (v) where, independently of one another, .epsilon. is 1 to 5, V' is oxygen, NH, a bond or a radical of the formula VI

in which U, V, W and Y are as defined above;
G can be C1-C12-alkanediyl, where alkanediyl can optionally be substituted by halogen, amino, hydroxyl, C1-C18-alkyl, C1-C18-alkoxy, C6-C14-aryl, or C6-C14-aryl-C1-C18-alkyl; C6-C14-aryl-di-C1-C12-alkanediyl, or a group of the formula (CH2CH2O) .delta.CH2CH2 in which 6 can be 1 to 11; or a bond; and G' is oxy, thio, imino, -C(O)-, -C(O)NH-, a bond or a radical of the formula VI in which U, V, W and Y are as defined above; and F and F' are linked by a bond and/or F is R0 - (A)k- V and F' in formula Ia is -(Q)1 - R1 and in formula lb is V1 - (A)1 - R1, where Ro is hydrogen, C1-C18-alkanoyl, C1-C18-alkoxy-carbonyl, C3-C8-cycloalkanoyl, C7-C15-aroyl, C3-C13-heteroaroyl or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridization of the oligomer onto a target nucleic acid, attacks the latter with binding, crosslinking or cleavage; or if k is zero, R0 is hydrogen or together with V is a radical of the formula VII

in which Z and Z' are, independently of one another, hydroxyl, mercapto, C1-C22-alkoxy, C1-C18-alkyl, C6-C20-aryl, C6-C14-aryl-C1-C18-alkyl, C1-C22-alkylthio, NHR3, NR3R4, or a group which favors intracellular uptake of the oligomer or serves as labeling of a DNA probe or, in the hybridi-zation of the oligomer onto a target nucleic acid, attacks the latter with binding, cross-linking or cleavage, and in which R3, R4 , V and W are as defined above;
R1 is hydrogen or Q o where R1 is always only hydrogen when at the same time 1 is zero and in formula Ia t is zero and s is 1 and Li1 is a struc-ture of the formula V with V' = bond, G= bond, e= 1 and G' = oxy, thio, imino or a radical of the formula VI with U = Z

or in formula lb q is 1 or q= r zero and in F' = V1 -(A)1 - R1 with V1 = V, A and Q are, independently of one another, the residue of a natural or unnatural amino acid;
Q o is hydroxyl, OR', NH2, NHR" with R' = C1-C18-alkyl and R" = C1-C18-alkyl, C1-C18-aminoalkyl, C1-C18-hydroxyalkyl;
V is as defined above;
V1 is a bond or V, where in F' only in for-mula Ib with q= zero and r = 1 V1 is always a bond;
k is zero to 10;
l is zero to 10;
with the proviso that a) if in the compound of the formula Ia t is zero and s is 1, and Li1 is (V' ) - (G) - (G') with V. = a compound of the formula VI, G = C2-C12-alkylene and G' = CO, in F' = -(Q)1 - R1 1 is zero to 10 and R1 is Q o;
b) if in the compound of the formula Ia s= t = zero, Li2 is a bond;
c) if in the compound of the formula Ib t is zero and s is 1, Li3 is a bond;
d) if in the compound of the formula lb s= t = zero, Li4 is a bond;

where each nucleotide is in its D configu-ration, and the base can be in the .alpha. or .beta. position, and the physiologically tolerated salts thereof.
2. The polyamide-oligonucleotide derivative selected from the group consisting of formulae la, lb and mixtures thereof, as claimed in claim 1 wherein the base customary in nucleotide chemistry is a natural base or the prodrug form thereof.
3. The polyamide-oligonucleotide derivative selected from the group consisting of formulae Ia, Ib and mixtures thereof, as claimed in claim 2 wherein the natural base is selected from the group consisting of adenine, cytosine, thymine, guanine, uracil, inosine and the prodrug forms thereof.
4. The polyamide-oligonucleotide derivative selected from the group consisting of formulae Ia, Ib and mixtures thereof, as claimed in claim 1 wherein the base customary in nucleotide chemistry is an unnatural base or the prodrug form thereof.
5. The polyamide-oligonucleotide derivative selected from the group consisting of formulae Ia, Ib and mixtures thereof, as claimed in claim 4 wherein the unnatural base is selected from the group consisting of purine, 2,6-diaminopurine, 7-deazaadenine, 7-deazaguanidine, N4,N4-ethanocytosine, N6,N6-ethano-2,6- diaminopurine, pseudoisocytosine, 5-methylcytosine, 5-fluorouracil, 5-(C3-C6)-alkynyluracil, 5-( C3-C6)-alkynylcytosine and the prodrug forms thereof.
6. The polyamide-oligonucleotide derivative selected from the group consisting of formulae Ia, Ib and mixtures thereof, as claimed in claim 1 wherein the residue of a natural or unnatural amino acid is selected from the group consisting of glycine, leucine, histidine, phenylalanine, cysteine, lysine, arginine, aspartic acid, glutamic acid, proline, tetrahydroisoquinoline-3-carboxylic acid, octahydroindole-2-carboxylic acid and N-(2-aminoethyl)glycine.
7. A polyamide-oligonucleotide derivative selected from the group consisting of formulae Ia, Ib and mixtures thereof, as claimed in claim 1, wherein the base is in the .beta. position.
8. A process for the preparation of polyamide-oligonucleotide derivatives as claimed in any one of claims 1 to 7, which comprises successive condensation of a PNA unit or DNA unit with, in each case, one nucleotide base onto an appropriately derivatized support or onto a growing oligomer chain.
9. A polyamide-oligonucleotide derivative as claimed in any one of claims 1 to 7 for use as medicine for the treatment of diseases caused by viruses or of diseases influenced by integrins or cell-cell adhesion receptors, for the treatment of cancer or for preventing restenosis.
10. A pharmaceutical composition containing a polyamide-oligonucleotide derivative as claimed in any one claims 1 to 7 and a pharmaceutical excipient.
11. A use of the polyamide-oligonucleotide derivative as claimed in any one of claims 1 to 7 as gene probe.
12. A polyamide-oligonucleotide derivative as claimed in any one of claims 1 to 7, wherein a nucleoside unit having a 3'-hydroxyl group is located on at least one end for use as primer.
13. The use as claimed in claim 11, wherein the gene probe is used in a homogeneous or heterogeneous assay for the determination of an oligo- or polynucleotide RNA or DNA target.
14. A use of the polyamide-oligonucleotide derivative as claimed in claim 12 in a gene probe assay for the determination of an oligo- or polynucleotide RNA or DNA target.
15. The use as claimed in claim 13 or 14, wherein the target is determined by hybridization after target amplification.
CA2144475A 1994-03-14 1995-03-13 Polyamide-oligonucleotide derivatives, their preparation and use Expired - Fee Related CA2144475C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DEP4408528.1 1994-03-14
DE4408528A DE4408528A1 (en) 1994-03-14 1994-03-14 Peptide oligonucleotide derivatives, their preparation and use

Publications (2)

Publication Number Publication Date
CA2144475A1 CA2144475A1 (en) 1995-09-15
CA2144475C true CA2144475C (en) 2010-06-08

Family

ID=6512694

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2144475A Expired - Fee Related CA2144475C (en) 1994-03-14 1995-03-13 Polyamide-oligonucleotide derivatives, their preparation and use

Country Status (14)

Country Link
EP (2) EP0672677B1 (en)
JP (1) JP4620810B2 (en)
KR (1) KR100416864B1 (en)
CN (1) CN100379756C (en)
AT (2) ATE335760T1 (en)
AU (1) AU698210B2 (en)
CA (1) CA2144475C (en)
DE (3) DE4408528A1 (en)
DK (2) DK0672677T3 (en)
ES (2) ES2179080T3 (en)
FI (2) FI117135B (en)
HK (2) HK1012003A1 (en)
NO (1) NO314664B1 (en)
PT (2) PT672677E (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6710164B1 (en) 1993-11-22 2004-03-23 Peter E. Nielsen Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US6150510A (en) 1995-11-06 2000-11-21 Aventis Pharma Deutschland Gmbh Modified oligonucleotides, their preparation and their use
DE4438918A1 (en) 1994-11-04 1996-05-09 Hoechst Ag Modified oligonucleotides, their preparation and their use
DE19502912A1 (en) * 1995-01-31 1996-08-01 Hoechst Ag G-Cap Stabilized Oligonucleotides
DE59607750D1 (en) * 1995-03-13 2001-10-31 Aventis Pharma Gmbh Phosphonomonoester nucleic acids, process for their preparation and their use
DE19532553A1 (en) * 1995-09-04 1997-03-06 Hoechst Ag Process for the preparation of substituted N-ethyl-glycine derivatives
GB2324534B (en) * 1996-01-06 2000-05-10 Danbiosyst Uk Composition for delivery of nucleic acid to a cell
DE69729145T2 (en) * 1996-05-24 2005-06-09 Aventis Pharma Deutschland Gmbh Reagent and method for inhibiting N-RAS expression
ATE334668T1 (en) * 1996-05-31 2006-08-15 Allelix Neuroscience Inc PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF NEUROLOGICAL AND NEUROPSYCHIATRIC DISEASES
US6191165B1 (en) * 1996-05-31 2001-02-20 Allelix Neuroscience Inc. Pharmaceutical for treatment of neurological and neuropsychiatric disorders
CA2261566A1 (en) * 1996-07-24 1998-01-29 Buchardt, Dorte Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
DE19637339A1 (en) * 1996-09-13 1998-03-19 Hoechst Ag Methods for amplifying nucleic acids
DE04020014T1 (en) 1997-09-12 2006-01-26 Exiqon A/S Bi-cyclic - nucleoside, nucleotide and oligonucleotide analogs
WO1999034014A2 (en) * 1997-12-23 1999-07-08 Roche Diagnostics Gmbh A method for the determination of a nucleic acid
US5952202A (en) * 1998-03-26 1999-09-14 The Perkin Elmer Corporation Methods using exogenous, internal controls and analogue blocks during nucleic acid amplification
DE19935303A1 (en) 1999-07-28 2001-02-08 Aventis Pharma Gmbh Oligonucleotides to inhibit the expression of human eg5
US6316230B1 (en) * 1999-08-13 2001-11-13 Applera Corporation Polymerase extension at 3′ terminus of PNA-DNA chimera
US7205105B2 (en) 1999-12-08 2007-04-17 Epoch Biosciences, Inc. Real-time linear detection probes: sensitive 5′-minor groove binder-containing probes for PCR analysis
DE10019135A1 (en) * 2000-04-18 2001-10-31 Aventis Pharma Gmbh Polyamide nucleic acid derivatives, agents and processes for their preparation
US7348146B2 (en) 2003-10-02 2008-03-25 Epoch Biosciences, Inc. Single nucleotide polymorphism analysis of highly polymorphic target sequences
SI1687609T1 (en) 2003-10-28 2015-03-31 Epoch Biosciences, Inc. Fluorescent probes for dna detection by hybridization with improved sensitivity and low background
DE102006034319A1 (en) * 2006-07-21 2008-01-31 Ugichem Gmbh Chiral phosphonic ester or phosphonic acid substituted compounds
EP2781523A1 (en) 2013-03-18 2014-09-24 Miltenyi Biotec GmbH Lipophilic oligonucleotide analogs

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989003849A1 (en) * 1987-10-28 1989-05-05 Howard Florey Institute Of Experimental Physiology Oligonucleotide-polyamide conjugates
WO1993024511A1 (en) * 1992-05-29 1993-12-09 Howard Florey Institute Of Experimental Physiology And Medicine Oligonucleotide-polyamide conjugates
US5138045A (en) * 1990-07-27 1992-08-11 Isis Pharmaceuticals Polyamine conjugated oligonucleotides
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
US5646261A (en) * 1992-01-22 1997-07-08 Hoechst Aktiengesellschaft 3'-derivatized oligonucleotide analogs with non-nucleotidic groupings, their preparation and use
NZ245720A (en) * 1992-01-22 1995-12-21 Hoechst Ag Oligonucleotide analogues; use as gene expression inhibitor or dna probe

Also Published As

Publication number Publication date
DK0672677T3 (en) 2002-10-28
JPH07278179A (en) 1995-10-24
EP0672677A2 (en) 1995-09-20
FI951132A0 (en) 1995-03-10
HK1038568A1 (en) 2002-03-22
KR100416864B1 (en) 2006-01-27
ES2179080T3 (en) 2003-01-16
PT1113021E (en) 2006-12-29
NO950955L (en) 1995-09-15
EP0672677A3 (en) 1996-01-17
FI20051072A (en) 2005-10-24
DK1113021T3 (en) 2006-12-11
EP0672677B1 (en) 2002-07-03
EP1113021B1 (en) 2006-08-09
PT672677E (en) 2002-11-29
CN1112126A (en) 1995-11-22
FI117135B (en) 2006-06-30
AU698210B2 (en) 1998-10-29
DE4408528A1 (en) 1995-09-28
ATE335760T1 (en) 2006-09-15
NO314664B1 (en) 2003-04-28
DE59511061D1 (en) 2006-09-21
ATE220070T1 (en) 2002-07-15
DE59510252D1 (en) 2002-08-08
AU1479895A (en) 1995-09-21
CA2144475A1 (en) 1995-09-15
ES2269239T3 (en) 2007-04-01
FI117939B (en) 2007-04-30
HK1012003A1 (en) 1999-07-23
JP4620810B2 (en) 2011-01-26
EP1113021A2 (en) 2001-07-04
KR950032265A (en) 1995-12-20
FI951132A (en) 1995-09-15
EP1113021A3 (en) 2001-07-11
NO950955D0 (en) 1995-03-13
CN100379756C (en) 2008-04-09

Similar Documents

Publication Publication Date Title
CA2144475C (en) Polyamide-oligonucleotide derivatives, their preparation and use
US6451968B1 (en) Peptide nucleic acids
EP1411063B1 (en) Peptide nucleic acids
US8268560B2 (en) Polymide nucleic acid derivatives, and agents and processes for preparing them
US6441130B1 (en) Linked peptide nucleic acids
US6713602B1 (en) Synthetic procedures for peptide nucleic acids
US7485421B2 (en) Polyamide-oligonucleotide derivatives, their preparation and use
CA2406168C (en) Polyamide nucleic acid derivatives, agents and methods for producing same
US20030105286A1 (en) Linked peptide nucleic acids

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20150313